| Excerpt | Reference |
|---|
| "A patient with AIDS who had no known psychiatric history and mild renal dysfunction experienced exacerbation of cytomegalovirus retinitis and was treated with ganciclovir 5 mg/kg iv q12h." | ( Brocavich, JM; Chen, JL; Lin, AY, 1992) |
| "A series of 66 AIDS patients with first-episode gastrointestinal CMV disease diagnosed on the basis of clinical and histopathologic findings were treated with foscarnet as first-line therapy at our institution between January 1987 and January 1991." | ( Blanshard, C, 1992) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "A 38-year-old bisexual man with acquired immunodeficiency syndrome (AIDS) who was being treated with oral acyclovir for herpetic stomatitis had a history of blurred vision OS that was diagnosed as cytomegalovirus retinitis." | ( Carter, JE; Shuster, AR, 1992) |
| "To study the incidence of AIDS-defining and non-AIDS-defining malignancies in injecting drug users with and without HIV infection in a methadone maintenance treatment program (MMTP)." | ( Budner, NS; Gachupin-Garcia, A; Selwyn, PA, 1992) |
| "A 32-year-old man diagnosed with acquired immunodeficiency syndrome and a disseminated cytomegalovirus infection experienced seizures associated with the administration of ganciclovir." | ( Barton, TL; Dever, LL; Roush, MK, 1992) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "In adults with the acquired immunodeficiency syndrome, long-term monotherapy with zidovudine selects for human immunodeficiency virus type 1 (HIV-1) strains with substantially reduced in-vitro susceptibility to the drug." | ( Maha, M; McKinney, RE; Mintz, M; O'Donnell, K; Rudoll, T; Santacroce, S; St Clair, MH; Tudor-Williams, G; Vavro, CL; Walter, E, 1992) |
| "Eight patients with AIDS and presumed or biopsy confirmed toxoplasmosis who were intolerant of or had not responded to standard therapies were treated with oral atovaquone 750 mg four times a day." | ( Kovacs, JA, 1992) |
| "In one patient with AIDS-related Kaposi's sarcoma, interferon-alpha (IFN-alpha) therapy increased 2, 5A synthetase activity twofold." | ( Ehmann, WC; Harvey, H; Kan, NC; Lipton, A; Miele, ME; Vesell, ES, 1992) |
| "The survival of 35 patients with AIDS or advanced HIV infection on treatment with zidovudine was related to the viral sensitivity to the drug and to the CD4+ cell count." | ( Gerstoft, J; Gøtzsche, PC; Nielsen, C; Nielsen, CM; Vestergaard, BF, 1992) |
| "Six subjects progressed to AIDS within the 2-year study period, confirming that the development of highly resistant isolates is not required for progression in treated individuals." | ( Boucher, CA; Darby, G; Goudsmit, J; Kellam, P; Lange, JM; Larder, BA; Mulder, JW; O'Sullivan, E; Ramautarsing, C, 1992) |
| "During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine." | ( Hansson, BG; Kroon, S; Moestrup, T; Sandström, E; Teglbjaerg, LL; Vestergaard, BF, 1992) |
| "A 30-yr-old man with acquired immunodeficiency syndrome treated with zidovudine developed biopsy-proven mitochondrial myopathy." | ( Cheema-Dhadli, S; Gopinath, R; Halperin, M; Hutcheon, M, 1992) |
| "In this prospective study, 26 AIDS patients with 32 episodes of PCP were treated with pentamidine (4 mg/kg/d)." | ( Comtois, R; Gervais, A; Lemieux, C; Pouliot, J; Vinet, B, 1992) |
| "Twenty-one acquired immunodeficiency syndrome (AIDS) patients received intravenous pentamidine as treatment of Pneumocystis carinii pneumonia (PCP)." | ( Balslev, U; Nielsen, TL, 1992) |
| "Seven patients with AIDS-related cognitive and emotional deficits had neuropsychologic testing and then were treated with methylphenidate or dextroamphetamine in individualized doses." | ( Angrist, B; d'Hollosy, M; Diamond, G; Sanfilipo, M; Satriano, J; Simberkoff, M; Weinreb, H, 1992) |
| "A further trial in AIDS patients with acyclovir-resistant HSV infection has been designed to define better the role of foscarnet maintenance and, in light of evidence that a significant proportion of initial recurrences are due to acyclovir-sensitive HSV, to examine the potential utility of acyclovir maintenance following foscarnet induction therapy." | ( Hardy, WD, 1992) |
| "Twenty-three AIDS treatment centers throughout Italy that reported cases to the National Registry of AIDS Cases between July 1987 and March 1988." | ( Agresti, MG; Floridia, M; Giuliano, M; Greco, D; Milazzo, F; Moroni, M; Pezzotti, P; Tomino, C; Vella, S; Visco, G, 1992) |
| "Described is how the National AIDS Committee of the Arab Gulf State of Qatar has managed medical and public education, screening of immigrant workers, and treatment of HIV-infected persons and AIDS cases." | ( Milder, JE; Novelli, VM, 1992) |
| "Thirty-five children diagnosed of AIDS were studied in order to evaluate toxicity and efficacy of oral Zidovudine treatment (AZT), as well as to analyze the clinical, biochemical, immunological and virological evolution of HIV infection throughout the treatment." | ( Cilleruelo Ortega, MJ; de José Gómez, MI; Fernández Calle, P; García Miguel, MJ; García Rodríguez, MC; González de Dios, J; Martín Fontelo, P; Martínez Zapico, R; Mellado Peña, MJ, 1992) |
| "In a recent AIDS Clinical Trials Group study comparing the efficacy of vidarabine and foscarnet in this indication, foscarnet therapy was found to be associated with statistically significant reductions in time to complete healing of lesions, cessation of viral shedding, and 50% reduction in pain, and all patients randomized to receive foscarnet had complete re-epithelialization of lesions." | ( Safrin, S, 1992) |
| "In conclusion, adult AIDS patients (homosexual or drug addicts) may benefit from treatment with ZDV, at least during 3 years." | ( Aznar, E; Batalla, J; Buira, E; Gatell, JM; Mallolas, J; Miró, JM; San Miguel, JG; Soriano, E; Zamora, L, 1992) |
| "Eight patients with AIDS were treated orally with 800 mg of fluconazole daily for cryptococcal meningitis for a mean duration of 4." | ( Berry, AJ; Graybill, JR; Rinaldi, MG, 1992) |
| "All six patients without AIDS experienced improvement or stabilization of their fungal infections while receiving high-dose itraconazole, although two patients later experienced treatment failures, one by relapse and one by progression, on lower doses." | ( Dunn, JF; Fetchick, RJ; Graybill, JR; Hardin, TC; Rinaldi, MG; Sharkey, PK, 1991) |
| "Forty-four patients with acquired immune deficiency syndrome with cytomegalovirus (CMV) retinitis (64 eyes) intolerant of or refusing systemic antiviral therapy received 710 intravitreal injections of ganciclovir at the dosage of 400 micrograms per injection." | ( Cochereau-Massin, I; Gharakhanian, S; Katlama, C; Lautier-Frau, M; Lehoang, P; Marcel, P; Matheron, S; Robinet, M; Rozenbaum, W; Zazoun, L, 1991) |
| "We report a case of a patient with AIDS who had disseminated sporotrichosis which was progressive and fatal despite antifungal therapy." | ( Fuhrer, J; Heller, HM, 1991) |
| "Ten new acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections occurred in the treated patients and 21 in the controls." | ( Abrams, D; Bartlett, J; Brewton, G; Galpin, J; Gill, P; Gorter, R; Gottlieb, M; Hersh, EM; Jonikas, JJ; Landesman, S, 1991) |
| "Symptomatic patients (ARC and AIDS) not receiving zidovudine (ZDV) therapy demonstrated a strong inverse relationship between serum EPO and hemoglobin levels (p = 0." | ( Bernstein-Singer, M; Gill, PS; Groshen, S; Levine, AM; Loureiro, C; Rarick, MU; Sullivan-Halley, J, 1991) |
| "Patients with AIDS-related complex experienced fewer adverse events and constitutional symptoms after IMREG-1 treatment." | ( Combs, KL; Cone, LA; Fiala, M; Gottlieb, MS; Henry, DH; Hillman, KS; Liebman, HA; Marcel, AJ; Vieira, J; Zackin, RA, 1991) |
| "Twenty-five patients with AIDS in AIDS Clinical Trials Group Protocol 002 were treated with either low or high dosages of zidovudine." | ( Armstrong, J; Fan, Z; Gupta, P; Huang, XL; McMahon, D; Pazin, G; Piazza, P; Rappocciolo, G; Rinaldo, C; Zhang, Z, 1991) |
| "Advanced AIDS-associated Kaposi's sarcoma often requires systemic cytotoxic chemotherapy." | ( Bernstein-Singer, M; Gill, PS; Jones, B; Levine, AM; Montgomery, T; Rarick, MU, 1990) |
| "Patients with acquired immunodeficiency syndrome (AIDS)-related epidemic Kaposi's sarcoma generally respond well to cytotoxic chemotherapy." | ( Akil, B; Bernstein-Singer, M; Espina, BM; Gill, PS; Krailo, M; McCutchan, JA; Muchmore, E; Parker, B; Rarick, M; Slater, L, 1991) |
| "The development of AIDS-defined opportunistic infections was relatively infrequent during therapy (14%)." | ( Akil, B; Bernstein-Singer, M; Espina, BM; Gill, PS; Krailo, M; McCutchan, JA; Muchmore, E; Parker, B; Rarick, M; Slater, L, 1991) |
| "Twenty-two patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex and multilineage hematopoietic defects were treated with recombinant granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) in a phase I/II trial." | ( Alton, NK; Baldwin, G; Glaspy, JA; Miles, SA; Mitsuyasu, RT; Moreno, J; Souza, L, 1991) |
| "Twelve male patients, eight with the acquired immunodeficiency syndrome (AIDS) and four with AIDS related complex (ARC), who had zidovudine associated neutropenia (less than 1 x 10(9) neutrophils/l) were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) in a phase I/II study." | ( Danner, SA; Lange, JM; van der Wouw, PA; van Leeuwen, R; van Oers, RH, 1991) |
| "Of the 35 patients with AIDS and M kansasii infection mentioned in the literature, only eight of these were described; and of the four patients (including our patient) who received therapy considered appropriate for this infection, only two survived." | ( Hodges, GR; Jost, PM, 1991) |
| "To assess trends in HIV infection and AIDS risk behaviors among intravenous drug users (IVDUs), a series of nonblinded point-prevalence surveys was conducted with admissions to methadone treatment in seven areas, including New York City; Trenton and Asbury Park, New Jersey; Baltimore; Chicago; San Antonio, Texas; and Los Angeles County between February and December 1987 (n = 713), January and June 1988 (n = 1,089), July and December 1988 (n = 932), and January and June 1989 (n = 1,110)." | ( Amsel, Z; Battjes, RJ; Pickens, RW, 1991) |
| "Three patients with AIDS who had cryptococcal meningitis were treated with liposomal amphotericin B after unsuccessful treatment with fluconazole and conventional amphotericin B." | ( Coker, RJ; Harris, JR; Murphy, SM, 1991) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "We have made progress in the therapy of AIDS-related malignancies, although it is obvious that our treatment strategies, at present, are not--by any measure--satisfactory." | ( Triozzi, PL, 1991) |
| "Seventy-two AIDS patients treated with ganciclovir for cytomegalovirus (CMV) disease were prospectively monitored for the development of drug-resistant virus." | ( Buhles, WC; Busch, DF; Drew, WL; Follansbee, SE; Gordon, SM; Gullett, J; Matthews, TR; Mehalko, SG; Miner, RC; Owen, WF, 1991) |
| "Zidovudine therapy of AIDS patients has been shown to cause only transient improvements in the numbers of circulating CD4+ cells and the in vitro functional activities of cultured lymphocytes." | ( Armstrong, JA; Hawk, H; Ho, M; McMahon, DK; Pazin, GJ; Winkelstein, A, 1991) |
| "We present here four patients with AIDS treated for toxoplasmic encephalitis who developed sulfadiazine-induced crystalluria." | ( Belenfant, X; Doco-Lecompte, T; Idatte, JM; Modai, J; Molina, JM, 1991) |
| "For zidovudine-treated AIDS/ARC patients, persistence of an aggregate antibody response 8 months after vaccination was associated with survival at 14 months after vaccination, whereas waning of response was not." | ( Aguirre, A; Glaser, JB; Schiffman, G; Simpkins, H; Volpe, S, 1991) |
| "The therapy of NHL-CNS in the AIDS patient makes use of corticosteroids followed by cranial irradiation." | ( Hochberg, FH; Loeffler, JS; Prados, M, 1991) |
| "Six out of 18 subjects progressed to AIDS after 60-126 weeks of treatment." | ( Bakker, M; Coutinho, RA; Goudsmit, J; Krijnen, P; Lange, JM; Mulder, JW, 1991) |
| "About two thirds of patients with Aids can be treated with zidovudine; in the others, the drug is ineffective or contraindicated." | ( Hirschel, B; Vanhems, P, 1991) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | ( Jones, WD; Shafer, RW, 1991) |
| "58 patients with AIDS or AIDS-related complex were studied with additional reference to the effect of previous treatment with zidovudine, and the effect of ddI on HIV-induced cognitive dysfunction." | ( Broder, S; Brouwers, P; Hartman, N; Johns, DG; Mitsuya, H; Pluda, JM; Thomas, RV; Wyvill, KM; Yarchoan, R, 1990) |
| "Seven patients developed AIDS (treatment group: 3, placebo group: 4), 1 patient died by homicide." | ( Bauer, P; Bendick, C; Bube, FW; Degenhardt, S; Fätkenheuer, G; Heiniger, HJ; Heitmann, K; Imbach, P; Rasokat, H; Schrappe-Bächer, M, 1990) |
| "A man with AIDS is described in whom a profound weight loss was converted into a weight gain by treatment with megoestrol acetate, a synthetic progesterone." | ( Goldberg, DJ; Green, ST; Heslop, JM; Kennedy, DH; Nathwani, D, 1990) |
| "In patients with the acquired immunodeficiency syndrome (AIDS), the rate of relapse after primary treatment for cryptococcal meningitis remains high." | ( Bozzette, SA; Chiu, J; Gilbert, G; Jacobsen, J; Larsen, RA; Leal, MA; McCutchan, JA; Robinson, P; Rothman, P; Tilles, J, 1991) |
| "In patients with AIDS, silent persistent infection is common after clinically successful treatment for cryptococcal meningitis." | ( Bozzette, SA; Chiu, J; Gilbert, G; Jacobsen, J; Larsen, RA; Leal, MA; McCutchan, JA; Robinson, P; Rothman, P; Tilles, J, 1991) |
| "Patients with cancer or AIDS who complain of anorexia and whose nutritional status is compromised may benefit from megestrol acetate therapy." | ( Heber, D; Hickman, M; Tchekmedyian, NS, 1991) |
| "The treatment of AIDS patients with zidovudine extends their survival time." | ( Borleffs, JC; Hoepelman, IM; Ligtenberg, PC; Vrehen, HM, 1991) |
| "Treatment of patients in the shadow of AIDS also poses unique problems for the clinician." | ( Stricker, RB, 1991) |
| "A 40-year-old patient with acquired immunodeficiency syndrome (AIDS) had an atopic dermatitis-like skin eruption and elevated serum IgE levels after therapy with AL721." | ( Ophir, J; Wolf, R; Yust, I, 1991) |
| "Cerebral toxoplasmosis related to AIDS was treated with a combination regimen of pyrimethamine, clindamycin, and spiramycin, and in a second trial with a combination of pyrimethamine and clindamycin." | ( Pohle, HD; Ruf, B, 1991) |
| "Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine." | ( Bini, T; Esposito, R; Foppa, CU; Gregis, G; Lazzarin, A; Moroni, M, 1991) |
| "A 16-item questionnaire about AIDS, HIV-1 transmission, and knowledge of safe sexual practices was administered to 228 subjects to determine background information." | ( Curran, P; Donegan, E; Miller, K; Shelley, TJ, 1990) |
| "Herein we present five cases of AIDS-related KS (EKS) with diffuse, superficial, and nodular oral lesions treated with dihematoporphyrin derivative and photodynamic therapy with subsequent dramatic early partial and complete responses." | ( Schweitzer, VG; Visscher, D, 1990) |
| "An approach to anti-AIDS chemotherapy is presented from the point of view of treating seropositive individuals by eliminating the infected dendritic cells that are the in vivo target of HIV-1." | ( Becker, Y, 1990) |
| "Of 18 AIDS patients with Pneumocystis carinii pneumonia treated with pentamidine mesylate parenterally, four developed serious to severe hypoglycaemia, three hypoglycaemia followed by insulin-requiring diabetes, and two others diabetes alone." | ( Assan, D; Assan, R; Bricaire, F; Leport, C; Perronne, C; Vilde, JL, 1990) |
| "Nine patients with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis on maintenance therapy with ganciclovir: 9(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) at high dose (30 mg/kg/week) or low dose (20 mg/kg/week) were tested every 1-2 weeks for CMV isolation from blood, saliva, and urine." | ( Hayes, K; Jennens, ID; Lucas, CR; Maclean, H; Sandland, AM, 1990) |
| "A patient with AIDS was admitted for acyclovir treatment of a persistent perirectal herpetic ulcer." | ( Gander, RM; Gateley, A; Johnson, PC; Kit, S; Kohl, S; Otsuka, H, 1990) |
| "Six men with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis, treated with combined ganciclovir induction therapy and hyperimmune globulin (CMV-IGIV) for 10 days followed by CMV-IGIV alone, had a median time to retinitis progression shorter (7 days) than had eight historical controls given ganciclovir maintenance therapy (54 days; P = 0." | ( Dionian, B; Jacobson, MA; Mills, J; O'Donnell, JJ; Rousell, R, 1990) |
| "Sixteen patients with the Acquired Immunodeficiency Syndrome (AIDS) and cytomegalovirus retinitis were treated with ganciclovir alone (9 patients) or ganciclovir and zidovudine (6 patients)." | ( Marsh, R; Millar, AB; Miller, RF; Mindel, A; Patou, G; Semple, SJ, 1990) |
| "All patients enrolled were men with the acquired immunodeficiency syndrome (AIDS) except one woman who was receiving prednisone therapy and was excluded from the final analysis." | ( Chan, LS; Larsen, RA; Leal, MA, 1990) |
| "Of 14 patients with AIDS assigned to fluconazole, 8 (57%; 95% CI, 29% to 82%) failed; none of the 6 patients with AIDS failed who were assigned to amphotericin B plus flucytosine therapy (0%; CI, 0% to 46%) (Fisher exact test, P = 0." | ( Chan, LS; Larsen, RA; Leal, MA, 1990) |
| "Ten patients with acquired immunodeficiency syndrome (AIDS) or related disorders, five of whom could not tolerate conventional doses of AZT, were administered rGM-CSF subcutaneously for 12 days." | ( Broder, S; Maha, M; McAtee, N; Myers, CE; Oette, D; Pluda, JM; Shay, LE; Smith, PD; Wahl, SM; Yarchoan, R, 1990) |
| "A total of 333 patients with AIDS and pneumocystis pneumonia received standard treatment and were randomly assigned to receive either corticosteroids (beginning with the equivalent of 40 mg of prednisone twice daily) or no additional therapy." | ( Abramson, I; Bartok, A; Bozzette, SA; Chiu, J; Coffman, J; Gluckstein, D; Kemper, C; Niosi, J; Sattler, FR; Wu, AW, 1990) |
| "During 20 months 49 AIDS patients treated with zidovudine were followed prospectively." | ( Buijs, L; Pietersz, RN; Reesink, HW; ten Veen, JH; van den Berg-Wolf, MG, 1990) |
| "Most PRBC transfusions administered to AIDS or ARC patients were optimal therapy." | ( Feigal, D; Jacobson, MA; Peiperl, L; Porteous, D; Toy, PT; Volberding, PA, 1990) |
| "As the AIDS epidemic has evolved, so have improvements been made in diagnosis and treatment of Pneumocystis carinii pneumonia, the most common opportunistic infection in AIDS." | ( Ettinger, NA, 1990) |
| "The substantial early mortality of AIDS-associated disseminated histoplasmosis and the modestly encouraging survival of those who were diagnosed in time to receive adequate therapy raise the issues of surveillance, prophylaxis, and empiric therapy for this infection in selected HIV-positive patients." | ( Burns, DK; Hernandez, JA; Nightingale, SD; Parks, JM; Pounders, SM; Reynolds, J, 1990) |
| "Four AIDS patients were intolerant to this drug and were treated with doxycycline and nifuroxazide." | ( Binet, D; Capella, F; Eliaszewicz, M; Frottier, J; Lecomte, I; Meyohas, MC; Poirot, JL, 1990) |
| "Since the first case of AIDS in Australia was diagnosed in December 1982, there have been substantial improvements in the treatment of AIDS-related conditions." | ( Cooper, DA; Solomon, PJ; Swanson, CE; Wilson, SR, 1990) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "It was shown that the AIDS type of Kaposi sarcoma responds to combined chemotherapy." | ( Bergmann, L; Helm, EB; Runne, U; Saller, R; Schöfer, H, 1986) |
| "We treated 12 patients who had acquired immunodeficiency syndrome and active HTLV-III/LAV viremia with suramin, a potent competitive inhibitor of reverse transcriptase, in six weekly induction doses of 1 g, followed by weekly maintenance doses of 500 mg." | ( Aguilar, S; Cohen, J; Formenti, SC; Gill, PS; Hawkins, JG; Krailo, M; Levine, AM; Meyer, PR; Parker, J; Rasheed, S, 1986) |
| "Twenty patients with Acquired Immune Deficiency Syndrome (AIDS) received treatment with Inosine Pranobex and specific antibacterial and anti-parasitic therapy." | ( Addo, E; McFarlane, H; Parsad, K, 1989) |
| "Some AIDS-related complex (ARC) and AIDS patients treated with zidovudine also showed a low T-cell response which diminished along with clinical deterioration." | ( Broder, S; Ghrayeb, J; Krohn, K; Lähdevirta, J; Mattinen, S; Ranki, A; Yarchoan, R, 1989) |
| "The treatment of patients with AIDS and AIDS-related complex (ARC) with zidovudine is limited by major haematological toxicity." | ( Cohen, H; Machin, SJ; Matthey, F; Miller, RF; Weller, IV; Williams, I, 1989) |
| "Treatment of AIDS patients with zidovudine is associated with an increase in lymphocyte counts." | ( Black, PH; Cohn, SE; Levy, EM; Liebman, H; Wu, JM, 1989) |
| "Twenty-two patients with the acquired immune deficiency syndrome (AIDS) and severe debilitating diarrhea caused by Cryptosporidium received eflornithine as therapy." | ( Bodey, GP; Fainstein, V; Rolston, KV, 1989) |
| "To assess the incidence of the AIDS dementia complex and the presence of HIV I p24 antigen in cerebrospinal fluid in relation to zidovudine treatment." | ( Bakker, M; Danner, SA; de Gans, J; Derix, MM; Goudsmit, J; Lange, JM; Portegies, P; Speelman, H, 1989) |
| "The incidence of AIDS dementia complex in patients with AIDS declined after the introduction of systematic treatment with zidovudine; the AIDS dementia complex might be prevented by inhibiting viral replication in the central nervous system." | ( Bakker, M; Danner, SA; de Gans, J; Derix, MM; Goudsmit, J; Lange, JM; Portegies, P; Speelman, H, 1989) |
| "In three of eight patients with the acquired immune deficiency syndrome the Pneumocystis carinii pneumonia treated with intravenous trimethoprim sulfamethoxazole, drug-related reactions occurred 9, 10, and 13 days after therapy." | ( Brunner, E; Haddad, ZH; Sainz, C; White, MV, 1989) |
| "Fifty-eight AIDS patients who previously had Pneumocystis carinii pneumonia (PCP) were enrolled in an open trial of zidovudine therapy." | ( Benson, CA; Kessler, HA; Murphy, RL; Phair, JP; Pottage, JC; Spear, JB; Steinberg, JP; Wallemark, CB, 1989) |
| "Thirty-four homosexual patients with AIDS were treated for Pneumocystis carinii pneumonia between April 1984 and November 1985." | ( Seitzman, PA; Shafer, RW; Tapper, ML, 1989) |
| "Therapy of patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) with azidothymidine (AZT) and 2'-3'-dideoxycytidine (ddC) is complicated by severe anemia, neutropenia, and thrombocytopenia, the cause of which is unknown." | ( Ganser, A; Greher, J; Hoelzer, D; Staszewski, S; Völkers, B, 1989) |
| "First, it was possible to treat the AIDS-patient as an outpatient with Candida esophagitis using orally administered fluconazole." | ( Goto, H; Goto, M; Mori, H; Nakata, H; Oka, S; Shimada, K; Tokitsu, M, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Physicians using ganciclovir in AIDS patients must watch for the signs of drug toxicity and adjust treatment accordingly." | ( Frank, I; Rubin, DH; Sinclair, SH; Weisenthal, RW, 1989) |
| "A patient with acquired immune deficiency syndrome (AIDS) with bilateral cytomegaloviral (CMV) retinitis who had become neutropaenic from intravenous gancyclovir, was treated with a total of 16 intravitreal 2 mg/0." | ( Heery, S; Hollows, F, 1989) |
| "The HIV-1 titers of seven patients with AIDS or AIDS-related complex treated with zidovudine for four weeks decreased significantly in plasma but not in PBMC." | ( Alam, M; Ho, DD; Moudgil, T, 1989) |
| "In 33 consecutive AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) we evaluated treatment, outcome, recurrence rate and pyrimethamine as chemoprophylaxis in a 1-year follow-up." | ( Bergdahl, S; Julander, I; Lidman, C; Lundbergh, P; Ortqvist, A, 1989) |
| "In acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) patients, orally and intravenously administered zidovudine is effective in reducing the incidence of opportunistic infections and neoplasms, increasing helper T lymphocyte numbers, and improving survival rates and quality of life." | ( Campoli-Richards, DM; Langtry, HD, 1989) |
| "Since the AIDS syndrome is probably a defect in net-work immunoregulation, the most appropriate target for therapy and for vaccination is the idiotype of anti-CD4 antibodies that block CD4/env interaction." | ( Dalgleish, AG; Habeshaw, JA, 1989) |
| "The mean SIE level for untreated AIDS patients (26." | ( Barnes, DC; Fuchs, E; Quinn, TC; Spivak, JL, 1989) |
| "A patient with acquired immunodeficiency syndrome (AIDS) showed longitudinal brownish-gray bands on several fingernails and toenails four months after starting therapy with azidothymidine." | ( Fisher, CA; McPoland, PR, 1989) |
| "To slow the spread of AIDS, it may be important for substance abuse treatment programs to give priority admission to patients who are HIV-infected and infectious." | ( Batki, SL; Good, P; Sorensen, JL; Wilkinson, K, 1989) |
| "In these AIDS patients, skin disease tends to be severe and recalcitrant to conventional therapy." | ( Belz, J; Breneman, DL; Nordlund, JJ; Solinger, A, 1989) |
| "Because most patients with acquired immunodeficiency syndrome and severe cytomegalovirus infection have required lifelong daily suppressive ganciclovir therapy to control disease progression, oral therapy appears to have practical advantages." | ( Brodie, HR; Burnette, T; Cederberg, DM; Cobb, E; de Miranda, P; Jacobson, MA; Mills, J, 1987) |
| "Forty patients with acquired immune deficiency syndrome (AIDS) and CMV retinopathy were treated with ganciclovir on a compassionate protocol basis." | ( Bryson, YJ; Champlin, RE; Frenkel, LM; Gottlieb, MS; Hardy, D; Holland, GN; Kreiger, AE; Sakamoto, MJ; Sidikaro, Y; Winston, DJ, 1987) |
| "Three patients with acquired immunodeficiency syndrome (AIDS) and disseminated cytomegalovirus (CMV) infection were treated with a new antiviral agent ganciclovir [9(1,3-dihydroxy-2-propoxymethyl) guanine] (DHPG)." | ( Bach, MC; Hedstrom, PS, 1987) |
| "We examined three patients with AIDS who had large, sharply demarcated areas of thinned retina consistent with inactive cytomegalovirus retinitis and who were not treated with ganciclovir." | ( Bozzette, S; Fay, MT; Freeman, WR; Hardy, D; Wiley, CA, 1988) |
| "The eyes of an AIDS patient with cytomegalovirus (CMV) retinitis and pneumonitis who died while receiving maintenance therapy with the antiviral agent 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (Ganciclovir) were obtained for pathological examination." | ( Castle, J; Friedman, AH; Orellana, J; Schmitterer, M; Siroty, W; Teich, SA, 1988) |
| "Nearly 50 percent of AIDS patients with previously treated cryptococcal meningitis will experience a relapse within six months." | ( Graybill, JR; Hartman, BJ; Murray, HW; Rowland, V; Sharkey, P; Squires, KE; Stern, JJ, 1988) |
| "Twenty-two patients with AIDS and various forms of cryptococcosis were treated in an open-label study with 50 to 400 mg/day of fluconazole." | ( Graybill, JR; Hartman, BJ; Murray, HW; Rowland, V; Sharkey, P; Squires, KE; Stern, JJ, 1988) |
| "Some two thirds of patients with AIDS can be treated with zidovudine; in the others the drug is ineffective (Kaposi's sarcoma) or contraindicated." | ( Hirschel, B, 1988) |
| "In December 1984, the chief of the AIDS Activities Division of San Francisco General Hospital's Department of Medicine hired a clinical pharmacist to develop the pharmacokinetics sections of investigational drug protocols, provide drug therapy consultations, and supervise the reorganization of the drug storage and inventory system." | ( Volberding, PA; Wong, RJ, 1988) |
| "We describe a patient with AIDS in whom recurrent drug eruption and fever following administration of various unrelated agents developed." | ( Ackerman, Z; Levy, M, 1987) |
| "Three patients with acquired immunodeficiency syndrome noted changing cutaneous reactions to mosquito bites one to three months after starting zidovudine therapy." | ( Diven, DG; Newton, RC; Ramsey, KM, 1988) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "A patient with acquired immunodeficiency syndrome (AIDS) developed rash, fever, neutropenia, and elevated liver function tests during an initial course of trimethoprim-sulfamethoxazole (TMP-SMX) therapy." | ( Arnold, PA; Guglielmo, BJ; Hollander, H, 1988) |
| "The remaining six patients had AIDS or probable AIDS and relapsed in five weeks or less after discontinuation of therapy." | ( Baird, B; Fujikawa, LS; Lane, HC; Manischewitz, J; Masur, H; Megill, M; Nussenblatt, RB; Palestine, AG; Rook, AH; Stevens, G, 1986) |
| "Twenty patients with the acquired immunodeficiency syndrome with CMV retinopathy were treated with a new, experimental, antiviral drug, 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (BW B759U), in dosages ranging from 5." | ( Frenkel, LM; Hardy, D; Holland, GN; Kreiger, AE; Sakamoto, MJ; Sidikaro, Y, 1986) |
| "A patient with acquired immune deficiency syndrome with bilateral cytomegalovirus retinitis was treated with intravitreal 200-micrograms/0." | ( Balfour, HH; Cantrill, H; Chinnock, BJ; Fletcher, C; Henry, K, 1987) |
| "Seventeen patients with the acquired immune deficiency syndrome and cytomegalovirus retinitis were treated with the antiviral drug ganciclovir (9-[1,3-dihydroxy-2-propoxy-methyl]-guanine, DHPG)." | ( Causey, D; Freeman, WR; Green, RL; Henderly, DE; Rao, NA; Trousdale, M; Wan, WL, 1987) |
| "Patients with the acquired immune deficiency syndrome (AIDS) with disseminated Mycobacterium avium infection have responded poorly to treatment with rifabutine (Ansamycin) and clofazimine, in spite of the good in vitro response of M." | ( Hadley, WK; Nassos, PS; Yajko, DM, 1987) |
| "The authors studied the eyes of three AIDS patients with CMV retinopathy who died while receiving ganciclovir chemotherapy." | ( Ambinder, RF; Bach, MC; Foos, RY; Frey, HM; Hodstrom, PS; Holland, GN; Newman, C; Pepose, JS; Quinn, TC, 1987) |
| "Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days." | ( Anderson, MG; Chanas, AC; Ellis, ME; Farthing, C; Gazzard, BG, 1987) |
| "Because of the increasing number of AIDS cases diagnosed every day, the need for an effective antiviral therapy is evident." | ( Hendricksen, C, 1988) |
| "Two hundred eighty-one patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex were enrolled in a double-blind, placebo-controlled trial of the efficacy and safety of orally administered zidovudine (azidothymidine or AZT)." | ( Bigley, JW; Drucker, JL; Evans, RW; Logue, PE; McKinnis, R; Schmitt, FA, 1988) |
| "A patient with AIDS-related thrombocytopenia (ART) was treated with the new anti-retroviral agent azidothymidine (AZT, Retrovir, zidovudine) by the intravenous and oral routes for a period of 20 weeks." | ( Chafey, S; Gottlieb, MS; Wolfe, PR, 1987) |
| "Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF)." | ( Cload, P; Danner, SA; de Gans, J; de Wolf, F; Derix, MM; Eeftinck Schattenkerk, JK; Goudsmit, J; Lange, JM; Ongerboer de Visser, BW, 1988) |
| "A 44-year-old man with acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) who suffered adverse effects from treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and was then treated with pentamidine isethionate is described, and approved and investigational drugs used in the management of PCP in the AIDS patient are discussed." | ( Hauptman, SP; Wordell, CJ, 1988) |
| "Pretreatment studies from 38 AIDS and AIDS-related complex (ARC) patients were comparably positive for virus isolation from their lymphocytes; all patients were qualitatively virus positive." | ( Allain, JP; Barry, DW; Fischl, MA; Leuther, MD; Makuch, RW; Nusinoff-Lehrman, S; Parks, ES; Parks, WP, 1988) |
| "Eight children with acquired immunodeficiency syndrome (AIDS), aged four months to 12 years, were treated with zidovudine (azidothymidine) 100 mg/m2 intravenously every six hours for 14 days, followed by oral zidovudine at the same dose for a total of six months." | ( Blanche, S; Burgard, M; Caniglia, M; Duhamel, G; Fischer, A; Griscelli, C; Rouzioux, C; Tardieu, M, 1988) |
| "We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure." | ( Ediger, SK; Isley, WL, 1988) |
| "A 47-year-old patient with AIDS and cerebral toxoplasmosis was treated with sulfadiazine pyrimethamine for 5 days." | ( Belshe, RB; Westblom, TU, 1988) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "Comparison was made with 12 AIDS patients with PCP who were not treated with steroids." | ( Brunton, J; Salit, IE; Walmsley, S, 1988) |
| "We report the treatment of nine AIDS patients, who had recurrent salmonellosis, with norfloxacin, a new oral fluoroquinolone which has excellent in vivo activity against Salmonella sp." | ( Appleman, MD; Causey, DM; Corrado, ML; Heseltine, PN; Leedom, JM, 1988) |
| "Thirty-five patients with the acquired immunodeficiency syndrome (AIDS) and central nervous system toxoplasmosis, seen over a 30-month period, were treated with the combination pyrimethamine/sulfadiazine." | ( Katlama, C; Leport, C; Marche, C; Matheron, S; Raffi, F; Regnier, B; Saimot, AG; Vedrenne, C; Vilde, JL, 1988) |
| "A 45-year-old man with the Acquired Immunodeficiency Syndrome (AIDS) and CNS toxoplasmosis presented with acute renal failure, hematuria, and renal colic shortly after starting treatment with sulfadiazine." | ( Appel, GB; Bendixen, B; Carbone, LG, 1988) |
| "carinii infection in the acquired immunodeficiency syndrome, a randomized double blind study of corticosteroid therapy for P." | ( Pella, JA; Rankin, JA, 1987) |
| "Treatment of AIDS patients with immunosuppressants should be examined." | ( Dierich, MP; Fuchs, D; Hausen, A; Hengster, P; Hoefler, E; Reibnegger, G; Schönitzer, D; Schulz, T; Wachter, H; Werner, ER, 1987) |
| "Six patients with acquired immunodeficiency syndrome and oral and esophageal candidiasis who had been treated with ketoconazole for more than 2 mo were evaluated with barium esophagram and endoscopy with biopsy and brush cytology." | ( Dincsoy, HP; Raufman, JP; Rosenthal, LE; Tavitian, A; Webber, CA; Weber, J, 1986) |
| "Forty-one homosexual men with the acquired immune deficiency syndrome (AIDS) or AIDS-related complex were treated with 0." | ( Abrams, DI; Feorino, P; Gottlieb, MS; Kaplan, LD; Kaufman, L; Kiprov, D; Levy, JA; Volberding, PA; Wolfe, PR; Wong, R, 1987) |
| "Ninety-eight patients with AIDS manifest as opportunistic infections (n = 38), AIDS with Kaposi's sarcoma (n = 38), AIDS-related complex (n = 20), or AIDS-associated non-Hodgkin's lymphoma (NHL) (n = 2) were treated with suramin sodium at 0." | ( Cheson, BD; Gill, P; Groopman, JE; Kaplan, LD; Levine, AM; Mildvan, D; Poiesz, BJ; Rios, A; Volberding, PA; Wolfe, P, 1987) |
| "Three patients with acquired immune deficiency syndrome (AIDS), central nervous system toxoplasmosis, and hypersensitivity to sulfadiazine were given treatment with clindamycin plus pyrimethamine." | ( Hoy, J; Rolston, KV, 1987) |
| "Six of nine patients with AIDS had a twofold improvement in lymphoproliferative response to at least one lectin with ribavirin treatment." | ( Bubley, G; Crumpacker, C; Finberg, R; Heagy, W; Hussey, S; Lee, TH; Lucey, D; McLane, MF; Monroe, JE; Schnipper, L, 1987) |
| "Four of five had the acquired immune deficiency syndrome (AIDS) and one was receiving steroid therapy." | ( Goldberg, DM; Mandell, W; Neu, HC, 1986) |
| "Twenty patients with the acquired immune deficiency syndrome (AIDS) and suspected Pneumocystis carinii pneumonia were evaluated by gallium67 (Ga67 scintigraphy and fiberoptic bronchoscopy for initial diagnosis and response to therapy." | ( Delaney, MD; Simon, GL; Tuazon, CU; Varma, VM; Witorsch, P, 1985) |
| "A 31-year-old man with acquired immunodeficiency syndrome and biopsy-proved Pneumocystis carinii pneumonia developed acute renal failure, elevated creatinine kinase levels, and myoglobin in both serum and urine while being treated with pentamidine." | ( Johnson, ES; Perez, G; Sensakovic, JW; Smith, LG; Suarez, M, 1985) |
| "In another group of 5 pre-AIDS patients thymopentin was administered via the subcutaneous route using 15 mg 3 times weekly; only 1 patient revealed immunological and clinical improvement." | ( Bolla, K; Clumeck, N; Cran, S; Duchateau, J; Mascart-Lemone, F; Van de Perre, P, 1985) |
| "In 8 of 18 homosexual men with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) treated with intravenous co-trimoxazole (trimethoprim-sulphamethoxazole) apparent drug-related complications developed during the course of acute therapy." | ( Abrams, DI; Ammann, AJ; Golden, JA; Jaffe, HS; Lewis, BJ, 1983) |
| "The loss of lean body mass accompanying acquired immunodeficiency syndrome (AIDS)-associated cachexia is refractory to current modes of therapy." | ( Butterfield, GE; Harrison, D; Hoffman, AR; Lieberman, SA, 1994) |
| "Four children with acquired immunodeficiency syndrome and aphthous oral ulcers with severe odynophagia were treated with a short oral course of prednisone." | ( Bernstein, LJ; de Asis, ML; Schliozberg, J, 1995) |
| "We report herein the case of an AIDS patient, treated with sulfadiazine because of Nocardia pneumonia, that came to the emergency room in acute renal failure." | ( Chechile Toniolo, G; Fariña, LA; Palou Redorta, J, 1995) |
| "Protocol 019 of the AIDS Clinical Trials Group (ACTG) investigated the efficacy of zidovudine monotherapy in asymptomatic patients with HIV infection." | ( Volberding, P, 1995) |
| "There was no significant difference in AIDS-free survival in the deferred-therapy group as compared with the low-dose or high-dose groups (81 cases of progression to AIDS or death vs." | ( Collier, AC; Fischl, MA; Grimes, JM; Hirsch, MS; Lagakos, SW; Meng, TC; Phair, JP; Rooney, J; Stein, DS; Volberding, PA, 1995) |
| "In addition, patients with AIDS also may exhibit a defect in adrenal function, potentiating the hyperkalemic effect of TMP therapy." | ( Hsu, I; Wordell, CJ, 1995) |
| "A total of 426 patients with AIDS or AIDS-related complex (ARC) who were intolerant to or clinically progressing on ZDV therapy and who had CD4+ cell counts < or = 150 x 10(6)/l were randomized to receive either a high (750 mg for bodyweight > or = 60 kg or 500 mg for bodyweight < 60 kg) or a low (200 mg and 134 mg, respectively) dose of ddI daily." | ( Arasteh, K; Haase, W; Jablonowski, H; Ruf, B; Schomaker, U; Schrappe, M; Staszewski, S; Stellbrink, HJ; Stoehr, A; von Eisenhart Rothe, B, 1995) |
| "Thirty-five AIDS patients (mean CD4 count 44 x 10(6)/L) with chronic cryptosporidiosis were treated with letrazuril at an initial oral daily dose of 50 mg in an open-label Phase I prospective trial." | ( Fong, I; Loeb, M; Phillips, J; Rachlis, A; Salit, I; Walach, C; Walmsley, S, 1995) |
| "Mortality and progression to AIDS rates were strongly associated with lower administration of CFC." | ( Altisent, C; Ayestarán, AI; Lorenzo, JI; Molina, R; Montoro, JB; Oliveras, J; Tusell, JM, 1995) |
| "Six patients on treatment for AIDS-associated complications were investigated and reviewed TPN that supplied energy equivalent to 1." | ( Deicher, H; Henkel, E; McMillan, DC; Melzer, A; Müller, MJ; Selberg, O; Süttmann, U, 1995) |
| "While approaches to HIV/AIDS education should include clinical treatment as the core, clinical knowledge alone will not promote the development of caring communities." | ( Opava, WD; Sowell, RL, 1995) |
| "Patients with AIDS-related KS are treated with a DOX-SL regimen every 2-3 weeks and are followed carefully for evidence of adverse treatment effects." | ( Eramo, LR; Gordon, KB; Guitart, J; Kuzel, TM; Tajuddin, A; VonRoenn, J, 1995) |
| "Thirty-four patients with AIDS-related advanced cutaneous/systemic KS were treated with 20 mg/m2 of LED every 3 weeks on an outpatient basis." | ( Harrison, M; Stewart, S; Tomlinson, D, 1995) |
| "Nine AIDS patients with acyclovir-unresponsive mucocutaneous herpes simplex virus infection were treated with thrice daily topical SP-303T ointment in an open-label pilot study." | ( McKeough, M; McKinley, G; Robinson, D; Safrin, S; Spruance, SL, 1994) |
| "Improved therapy for AIDS dementia and related encephalopathies may be achieved through enhanced delivery of effective antiretroviral agents to the central nervous system (CNS)." | ( Anderson, WR; Biegon, A; Brewster, ME; Harish, Z; Mizrachi, Y; Rubinstein, A, 1995) |
| "We present a case of AIDS with idiopathic esophagic fistula which had a positive response to steroid therapy." | ( García Calvo, MI; Gómez Huelgas, R; Retamero Orta, MD; Santalla Peciña, F; Trillo Belizón, C, 1995) |
| "Seven AIDS patients with central nervous system (CNS) disease and cytomegalovirus (CMV) DNA in cerebrospinal fluid (CSF) were evaluated before and 3 weeks after standard ganciclovir treatment by nested polymerase chain reaction (PCR) on limiting dilutions and by quantitative PCR." | ( Baldanti, F; Castagna, A; Cinque, P; Furione, M; Lazzarin, A; Lillo, F; Linde, A; Monforte, AD; Terreni, MR; Vago, L, 1995) |
| "Among the 861 patients with AIDS treated in our unit from 1991 to 1993, 7 cases involving cytomegalovirus infection of the conus medullaris and/or the cauda equina were studied retrospectively." | ( el Amrani, M; Girard, PM; Gozlan, J; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W, 1995) |
| "Therapy of pediatric AIDS utilizes antiretroviral compounds; antibiotic, antifungal, and antiparasitic agents; and both active and passive immunization in a multifactorial approach." | ( Capparelli, EV; Connor, JD; Wu, LR, 1995) |
| "Sixteen AIDS patients treated for oropharyngeal candidosis with FCZ were studied." | ( Dromer, F; Dupont, B; Garcia-Hermoso, D; Improvisi, L; Provost, F, 1995) |
| "In an AIDS patient with diarrhea, identical isolates of Campylobacter jejuni susceptible and, later, resistant to macrolide antibiotics were isolated from feces before and after treatment with clarithromycin." | ( Altwegg, M; Baumann, R; Funke, G; Penner, JL, 1994) |
| "USE OF CD4 CELL COUNTS AS A MARKER OF AIDS: Most trials of zidovudine treatment have shown a slower decline in CD4 cell counts." | ( Dormont, J, 1994) |
| "We observed an AIDS patient who suffered from NMS following treatment with clotiapine for insomnia and agitation." | ( Casadei, G; De Massis, P; Gabellini, AS; Grillo, A; Pezzoli, A; Sacquegna, T, 1994) |
| "In a phase I trial of stavudine in AIDS or AIDS-related complex (ARC), antiviral effects and safety were assessed in 41 patients treated with dosages of 0." | ( Anderson, RE; Cross, A; Dunkle, LM; Hassett, J; Murray, HW; Sacks, HS; Sledz, S; Squires, KE; Weiss, W, 1995) |
| "Three-year AIDS-free survival probability estimates since therapy start." | ( Barcherini, S; Bucciardini, R; Chiesi, A; Floridia, M; Giuliano, M; Mariotti, S; Seeber, A; Tomino, C; Vella, S, 1995) |
| "The survival of 35 patients with AIDS or advanced HIV infection on zidovudine treatment was related to the viral sensitivity to the drug and to the CD4+ cell count." | ( Gerstoft, J; Gøtzsche, PC; Nielsen, C; Nielsen, CM; Vestergaard, BF, 1994) |
| "Since the first case report of acquired immunodeficiency syndrome (AIDS) in patients with hemophilia from our department in 1994, we have treated more than 60 hemophiliacs infected with human immunodeficiency virus type-1 (HIV-1)." | ( Matsuda, J, 1994) |
| "We hypothesize that the AIDS pandemic may have originated with a contaminated polio vaccine that was administered to inhabitants of Equatorial Africa from 1957 to 1959." | ( Elswood, BF; Stricker, RB, 1994) |
| "Treatment of AIDS-related Kaposi's sarcoma with cytotoxic chemotherapy is limited by toxicities of the various agents." | ( Kern, P; Kern, WV; Wagner, D, 1994) |
| "Gene therapy for AIDS requires the identification of genes which effectively inhibit HIV-1 replication coupled to an efficient vector system for gene delivery and expression." | ( Bahner, IC; Kohn, EB; Larson, GP; Rossi, JJ; Zaia, JA; Zhou, C, 1994) |
| "One approach to gene therapy for AIDS is to block the replication of human immunodeficiency virus type 1 (HIV-1) by inhibiting that tat gene, whose product activates the expression of all HIV-1 genes." | ( Chang, HK; Ensoli, B; Lisziewicz, J; Peng, B; Sun, D; Thomson, M; Trapnell, B, 1995) |
| "The lag time for adoption of new acquired immunodeficiency syndrome (AIDS) therapies into the clinical practices of different types of ambulatory care providers can be estimated from patient use of zidovudine therapy during the first few years after approval by the Food and Drug Administration." | ( Cosler, LE; Markson, LE; Turner, BJ, 1994) |
| "In 1987, 55% of those who had an AIDS specialist as their dominant care provider received zidovudine therapy, compared with only 36% of patients with a primary care clinic as their dominant care provider." | ( Cosler, LE; Markson, LE; Turner, BJ, 1994) |
| "In our AIDS study population, there was at least a 3-year lag before patients of primary care clinics received zidovudine therapy at the same rate as patients of AIDS specialists." | ( Cosler, LE; Markson, LE; Turner, BJ, 1994) |
| "Knowledge of AIDS and its transmission was studied in patients undergoing drug-dependence treatment for opiates and/or cocaine." | ( Barrio, G; Bravo, MJ; Bueno, A; de la Fuente, L; Lardelli, P; López, R, 1994) |
| "Almost all patients with acquired immunodeficiency syndrome and successfully treated esophageal candidiasis develop a recurrence, usually within 2-3 months." | ( Laine, L, 1994) |
| "However, naive subsets from AIDS patients still displayed differential requirements since they failed to replicate HIV-1 after treatment with PMA and rTNF-alpha." | ( Cayota, A; Dighiero, G; Feuillie, V; Scott-Algara, D; Vuillier, F, 1993) |
| "Forty patients with AIDS-associated Kaposi's sarcoma (KS) treated with the combination of interferon alpha-2b (IFN-alpha) 10-20 MU day-1 and zidovudine (ZDV), 500-800 mg day-1, were evaluated for safety and efficacy." | ( Bolao, F; Casanova, A; Clotet, B; García, P; Gudiol, F; Pagerols, X; Podzamczer, D, 1993) |
| "In patients who had not progressed to AIDS by week 16, most of the subsequent zidovudine effect in reducing the risk for progression could be explained by its effect on net CD4+ percent (percentage of CD4+ lymphocytes among all leukocytes) for the first 16 weeks of therapy." | ( Choi, S; Lagakos, SW; Schooley, RT; Volberding, PA, 1993) |
| "Variables within 6 months prior to AIDS diagnosis included age, CD4+ lymphocyte counts, hemoglobin, and self-reported thrush, fever, anti-retroviral therapy (ART) beginning prior to AIDS onset, and ART beginning after AIDS (as a time-dependent covariate) were analyzed as mutually exclusive categories, as was prophylaxis for Pneumocystis carinii pneumonia (PCP)." | ( He, Y; Hoover, DR; Kingsley, LA; Phair, JP; Saah, AJ, 1994) |
| "Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65% had measurable pretreatment concentrations of serum p24 antigen (> or = 10 pg/mL)." | ( Arduino, JM; Balfour, HH; Beckett, LA; Coombs, RW; DeGruttola, V; Fischl, MA; Hollinger, FB; Rasheed, S; Volberding, P, 1994) |
| "A 25-year-old woman with AIDS was submitted to HLA-identical allogeneic BMT after cytoablation with busulphan and cyclophosphamide and combined anti-HIV-1 therapy with zidovudine, IFN-alpha 2 and anti-HIV-1-specific T cell clones." | ( Arras, M; Boero, R; Carcassi, C; Contu, L; La Nasa, G; Ledda, A; Orrù, S; Pintus, A; Pizzati, A; Vacca, A, 1993) |
| "When initiated after the time of AIDS diagnosis, zidovudine was associated with improved prognosis but for no more than 2 years after starting therapy." | ( Clumeck, N; Gatell, JM; Johnson, AM; Ledergerber, B; Lundgren, JD; Nielsen, JO; Pedersen, C; Phillips, AN; Vella, S, 1994) |
| "Thus, the AIDS patients with anemia and serum erythropoietin levels < or = 500 IU/L treated with recombinant human erythropoietin showed increased mean hematocrit and improved health perceptions and energy levels." | ( Brown, RE; Henry, DH; McNeill, MV; Revicki, DA; Rios, A; Watson, T, 1994) |
| "This article addresses the effects of AIDS on nurses and presents a model for nursing administrators to establish and maintain a supportive, caring environment for nurses." | ( Brewington, JG, 1994) |
| "Nine German AIDS treatment centers entered case reports dating from January 1988 to January 1992." | ( , 1994) |
| "The acquired immunodeficiency syndrome (AIDS) epidemic represents a modern-day plague that has not only resulted in a tragic loss of people from a wide spectrum of society but has reshaped our viewpoints regarding health care, the treatment of infectious diseases, and social issues regarding sexual behavior." | ( Morrow, CD; Park, J; Wakefield, JK, 1994) |
| "In this study we treated groups of MAIDS-infected mice with combinations of pentoxifylline, an agent which increases cAMP and inhibits phosphodiesterases, and sodium meclofenamic acid, a PgE2 inhibitor." | ( Ambrus, JL; Butsch, J; Chadha, KC; Mathur, N; Munschauer, F; Nakeeb, S; Satchidanand, SK; Stadler, I; Toumbis, C; Vladutiu, A, 1994) |
| "A 36-yr-old Hispanic man with AIDS was on long-standing aerosolized pentamidine therapy in 1986." | ( Abourizk, NN; Lyons, RW; Madden, GM, 1993) |
| "In particular, in patients with AIDS who are more susceptible for adverse drug reactions and who are simultaneously receiving a variety of drugs with a considerable potential of cutaneous side effects, therapy cannot be withhold for lack of therapeutic alternatives." | ( Bircher, A; Haefeli, WE; Leib, SL; Lüscher, TF; Schlienger, RG, 1993) |
| "Patients with AIDS often experience recurrent infections with varicella-zoster virus (VZV) requiring repeated or prolonged treatment with acyclovir (ACV), which may lead to the development of ACV resistance." | ( Biron, KK; Phelps, WC; Talarico, CL, 1993) |
| "Five patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC) and intractable diarrhea were treated with daily colonic insufflations of medical ozone (oxygen/ozone mixture) for 21-28 days." | ( Carpendale, MT; Freeberg, J; Griffiss, JM, 1993) |
| "The cumulative incidence of AIDS was significantly lower in 40 transplant patients with an immunosuppressive regimen including cyclosporine than in 13 transplant patients receiving immunosuppressive treatment without cyclosporine (5-year cumulative risk of AIDS: 31% versus 90%, P = 0." | ( Bennhold, I; Keller, F; Krause, PH; L'age-Stehr, J; Mihatsch, MJ; Offermann, G; Schwarz, A, 1993) |
| "In patients with acquired immunodeficiency syndrome, the traditional treatments are frequently accompanied by local and generalized side effects that are detrimental to an already compromised immune system." | ( Lucatorto, FM; Sapp, JP, 1993) |
| "Cryptosporidiosis in patients with AIDS often leads to a severe wasting illness that is difficult to treat." | ( Fichtenbaum, CJ; Powderly, WG; Ritchie, DJ, 1993) |
| "Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment." | ( Feinberg, J; Fischl, MA; Groopman, JE; Kahn, J; Krown, SE; Miles, S; Mitsuyasu, R; O'Boyle, KP; Volberding, PA; Wernz, JC, 1993) |
| "Sixty-one patients with AIDS were diagnosed and treated between July 1987 and June 1992." | ( Babu, PG; Chacko, S; Jacob, M; Jayakumari, H; John, TJ; Kaur, A; Ramachandran, P; Saraswathi, NK; Selvaraj, R; Tripathy, SP, 1993) |
| "A 65-year-old woman with the acquired immunodeficiency syndrome (AIDS) complicated by recurrent mucocutaneous herpes simplex virus (HSV) infection developed angioedema on the initiation of her second course of oral acyclovir therapy." | ( Christopher, GW; Hartle, JE; Henry, RE; Wegmann, JA, 1993) |
| "Two patients with AIDS and inflammatory arthritis were treated with HCQ, which was given in a loading dose of 600 mg/day." | ( Ornstein, MH; Sperber, K, 1996) |
| "Progression to AIDS or severe AIDS-related complex occurred in six zidovudine (ZDV)- and six placebo-treated subjects." | ( Endert, E; Godfried, MH; Lange, JM; Mulder, JW; Sauerwein, HP; van der Poll, T; Weverling, GJ, 1995) |
| "Sera obtained from AIDS patients with cytomegalovirus (CMV) retinitis before and after treatment with foscarnet, AIDS patients with human immunodeficiency virus (HIV) retinopathy, AIDS patients without retinal disease, and normal healthy controls with and without positive CMV serologies were assayed for the presence of antibodies against the 200-kDa outer, 160-kDa middle, and 68-kDa core subunits of the neurofilament triplet." | ( Cunningham-Rundles, S; Heinemann, MH; Klein, RF; Polsky, B; Rosberger, DF; Tshering, SL, 1994) |
| "The resistance of acquired immunodeficiency syndrome (AIDS) to traditional drug therapy has prompted a search for alternative treatments for this disease." | ( Nabel, GJ; Ranga, U; Woffendin, C; Xu, L; Yang, Z, 1996) |
| "One of the blood donors was an AIDS patient who had been treated at the same hospital in 1991 and who had died in 1993." | ( Chen, YM; Chung, YM; Liu, CY; Su, YL; Wang, WW; Yao, C, 1996) |
| "In patients with advanced AIDS, the prophylactic administration of clarithromycin is well tolerated, prevents M." | ( Craft, JC; Crampton, S; Cynamon, M; Heifets, L; Henry, D; Jablonowski, H; Jemsek, J; LaMarca, A; Montecalvo, M; Notario, G; Pierce, M; Wormser, GP; Yangco, BG, 1996) |
| "Antiviral therapy for AIDS has focused on the discovery and design of inhibitors for two main enzyme targets of the human immunodeficiency virus type 1 (HIV)--reverse transcriptase (RT) and protease (PR)." | ( Burt, SK; Erickson, JW, 1996) |
| "A child with AIDS is presented who developed L1-ALL while being treated for L3-AL." | ( Astigarraga, I; Cardenal, I; Fernández-Teijeiro, A; Navajas, A; Piñán, MA, 1996) |
| "Of 136 patients with AIDS, 63 received clarithromycin 500 mg twice daily, and 73 patients not treated with clarithromycin represented the control group." | ( Jordan, WC, 1996) |
| "Since then, many patients with AIDS have been treated with this drug." | ( al-Hedaithy, MA; Noreddin, AM, 1996) |
| "Guided by the AIDS Risk Reduction Model (ARRM), psychosocial correlates of HIV risk behavior were examined among noninjection cocaine dependent, heterosexual men (NI-CD-HM) in treatment." | ( Ireland, SJ; Malow, RM, 1996) |
| "Thirty-six HIV-positive, pre-AIDS individuals (100-500 CD4+ cells/mm3) who had had at least six months of zidovudine therapy received polyI:polyC12U (400 or 700 mg) or placebo twice weekly with zidovudine." | ( Carter, WA; Hamill, AK; Klimas, N; Molavi, A; Salvato, PD; Strayer, DR; Thompson, CE; Thompson, KA; Ventura, D; Zheng, Z, 1996) |
| "The survival from AIDS or CD4 count = 50 cells/mm3 did not differ significantly between those with treated CTOX and a control group who had no toxoplasma infection, suggesting that treatment is reasonably effective." | ( Brettle, RP; Burns, SM; Flegg, PJ; Laing, RB; Leen, CL, 1996) |
| "A 28-year-old man with AIDS developed hyperglycemia requiring insulin therapy 5 days after beginning megestrol therapy." | ( Garcia Diaz, B; Gonzalez Del Valle, L; Herrero Ambrosio, A; Jimenez Caballero, E; Martinez Hernandez, P, 1996) |
| "We have individually treated ten AIDS patients whose CD4 numbers were inferior to 200/mm3, with the five following HIV1 virostatics: a) azido-deoxythymidine (AZT), dideoxyinosine (ddI) and dideoxycytidine (ddC), which affect the same viral target, retrotranscriptase, b) acriflavine (ACF) and methyl-hydroxy-ellipticine (MHE) which we have discovered to be strong virostatics in vivo, in mice, against Friend's virus, and in man, against AZT resistant HIV1." | ( Ambetima, N; Blanquet, D; Hallard, M; Mathé, G; Morette, C; Orbach-Arbouys, S; Pontiggia, P; Triana, K, 1996) |
| "Pneumothorax in patients with AIDS is associated with a high rate of intercurrent PCP; a low threshold for treating this infection presumptively is indicated." | ( al-Kattan, K; Asboe, D; Fisher, M; Gazzard, BG; Kaplan, DK; Nelson, MR, 1996) |
| "In HIV+/AIDS patients with the lowest CD4+ counts (those on DDI monotherapy), utilization of Marinol/marijuana does not seem to have a deleterious impact." | ( Bechtel, LM; Starich, GH; Whitfield, RM, 1997) |
| "A 37-year-old AIDS patient suffering from wasting syndrome and hypogonadism was treated with 1 alpha-dihydrotestosterone." | ( Dobmeyer, JM; Dobmeyer, TS; Helm, EB; Hoelzer, H; Klauke, S; Klein, SA; Rossol, R, 1997) |
| "Fifty-three patients with advanced AIDS-KS who experienced disease progression or intolerable toxicities while receiving standard doxorubicin/bleomycin/vincristine (ABV) or bleomycin/vincristine (BV) chemotherapy were identified from a cohort of patients who were then treated with pegylated-liposomal doxorubicin." | ( Dezube, BJ; Dosik, GM; DuMond, C; Krown, SE; Levine, R; Mamelok, RD; Northfelt, DW; Rios, A; Thommes, JA; Von Roenn, JH, 1997) |
| "IDU began pre-AIDS antiretroviral therapy significantly later than homosexual men and heterosexuals, even after adjusting for CD4 count." | ( Alliegro, MB; Dorrucci, M; Pezzotti, P; Phillips, AN; Rezza, G, 1997) |
| "When AIDS patients treated with zidovudine were compared with those not given this medication, differences in the urinary excretion of acetaminophen and its metabolites were not observed." | ( Boix, V; Esteban, A; González, M; Mora, A; Pérez-Mateo, M; Portilla, J, 1997) |
| "Of the 156 AIDS patients, 93 had been treated with zidovudine sometime during their follow up, 60 had received primary and 50 secondary Pneumocystis carinii pneumonia (PCP) prophylaxis." | ( Beck, EJ; Forster, GE; Goh, BT; Hillman, RJ; Mandalia, S; Rogers, PA; Satterthwaite, H, 1997) |
| "The use of DHEA for the treatment of AIDS shows some promise, although controlled trials have not been performed to evaluate its efficacy." | ( Abate, MA; Centurelli, MA, 1997) |
| "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy." | ( Bullis, JE; Cronkite, EP; Hirabayashi, Y; Inoue, T; Mitsui, H; Umemura, T, 1997) |
| "Eighteen consecutive AIDS patients with a first episode of cryptococcal meningitis were enrolled in the study to evaluate the efficacy and tolerability of amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS." | ( Jaruratanasirikul, S, 1996) |
| "Four consecutive AIDS patients with psoriasis and CD4 count lower than 20/mm3 were treated with 8-methoxypsoralen and UVA (PUVA)." | ( Krischer, J; Lemonnier, E; Pechère, M; Perrin, L; Saurat, JH; Yerly, S, 1997) |
| "We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy." | ( Hartzband, P; Lally, M; Sakoulas, G; Tritos, NA; Wanke, C, 1997) |
| "ALA-PDT treated AIDS patient suffering from Molluscum contagiosum or a kidney transplant patient with Verrucae vulgares showed greatly improved clinical symptoms one month after treatment." | ( Ben-Hur, E; Malik, Z; Mendelson, E; Orenstein, A; Smetana, Z, 1997) |
| "Forty-six AIDS patients with mild to moderate disseminated histoplasmosis who had successfully completed 12 weeks of induction treatment with itraconazole were treated with itraconazole, 200 mg once daily (42 patients) or 400 mg once daily (4 patients)." | ( Bartlett, JA; Clark, R; Hafner, R; Hecht, FM; Jacobson, JM; Keefer, MC; Korzun, AH; Lai, KK; Larsen, R; Limjoco, MT; Powderly, W; Schneider, D; Simpson, M; Skahan, KJ; Squires, K; Wheat, J, 1997) |
| "In the AIDS patient, empiric therapy based on clinical presentation has its proponents." | ( Baughman, RP; Liming, JD, 1998) |
| "Three patients with AIDS in whom multifocal choroiditis and choroidal lesions were the initial signs of disseminated cryptococcosis were treated with systemic amphotericin B and flucytosine." | ( Dugel, PU; Kolahdouz-Isfahani, A; Rao, NA; Rostomian, K; Smith, RE; Thach, AB, 1997) |
| "The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy." | ( Collier, AC; Coombs, RW; D'Aquila, RT; DeGruttola, V; Fischl, MA; Hammer, SM; Hughes, MD; Johnson, VA; Katzenstein, DA; Marschner, IC; Richman, DD; Saag, MS; Smeaton, LM; Spector, SA, 1998) |
| "Patients with AIDS frequently require long-term central venous access devices for intravenous (IV) therapy." | ( Grant, P; Keiser, P; Skiest, DJ, 1998) |
| "These findings show that AIDS-associated KS can be effectively treated after photosensitization with ICG and subsequent irradiation with an appropriate diode laser." | ( Abels, C; Bäumler, W; Goetz, AE; Karrer, S; Landthaler, M; Szeimies, RM, 1998) |
| "Eleven AIDS patients receiving HAART with healed CMV retinitis in whom CMV-specific maintenance therapy was discontinued were studied." | ( Freeman, WR; Karavellas, MP; Macdonald, JC; Morse, LS; Reed, JB; Torriani, FJ, 1998) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| "We describe a patient with AIDS who was being treated with the cidofovir/probenecid combination for a peri-anal acyclovir-resistant herpetic infection." | ( Engler, RJ; Katial, RK; Myers, KW, 1998) |
| "Many patients with HIV/AIDS are now being treated with two or more drugs to reduce HIV viraemia and boost CD4 T-cell counts." | ( Greenwood, I; Heylen, R; Zakrzewska, JM, 1998) |
| "In 26 AIDS patients treated for toxoplasmic encephalitis, the inhibitory effect on Toxoxplasma growth of sequential sera taken before and after initiation of therapy was determined using a culture-based immunoassay and compared with pyrimethamine blood levels." | ( Derouin, F; Farinotti, R; Gérard, L; Leport, C; Maslo, C, 1998) |
| "Three acquired immune deficiency syndrome patients given foscarnet to treat cytomegalovirus retinitis developed renal failure with crystal deposits within the renal glomeruli." | ( Beaufils, H; Daudon, M; Jouanneau, C; Katlama, C; Lacour, B; Maurice-Estepa, L; Sazdovitch, V, 1998) |
| "While treatment against HIV and AIDS has improved, curative therapy remains to be developed." | ( Catton, MG, 1996) |
| "Optimal delivery of chemotherapy in AIDS patients with Kaposi's sarcoma (KS) is frequently limited by hematological toxicity, mainly neutropenia." | ( Cancellieri, C; Chiodo, F; Coronado, O; Manfredi, R; Mastroianni, A; Pignatari, S, 1998) |
| "marneffei infection in patients with the acquired immunodeficiency syndrome (AIDS) who were in complete remission after treatment for culture-proved P." | ( Nelson, KE; Perriens, J; Sirisanthana, T; Supparatpinyo, K, 1998) |
| "A 32-year-old man with acquired immunodeficiency syndrome (AIDS) admitted to the hospital for treatment of visceral leishmaniasis was inadvertently given 10 times the prescribed first dose of sodium stibogluconate ([Sb] 6." | ( Desmeules, J; Reymond, JM, 1998) |
| "But in AIDS groups tritherapies are applied not only in a continuous fashion, but in an identical form and for an undefined time, the process which is used in experimental cancer chemotherapy to induce resistant cell lines." | ( Mathé, G, 1997) |
| "This was a substudy of AIDS Clinical Trials Group (ACTG) protocol 175, a phase II/III study of dideoxynucleoside monotherapy versus combination therapy in asymptomatic HIV-positive subjects." | ( Blaschke, TF; Girard, P; Kastrissios, H; Katzenstein, D; Sheiner, LB; Suárez, JR, 1998) |
| "This was a substudy of AIDS Clinical Trials Group protocol 175, a large, double-blind, randomized study of monotherapy versus combination dideoxynucleoside therapy." | ( Blaschke, TF; Hammer, S; Kastrissios, H; Katzenstein, D; Suárez, JR, 1998) |
| "A 57-year-old man with AIDS, who had been treated with zidovudine for 3 years, developed fatigue and weight loss." | ( Chariot, P; Chazaud, B; de Lacroix-Szmania, I; Drogou, I; Eliezer-Vanerot, MC; Lombès, A; Schaeffer, A; Zafrani, ES, 1999) |
| "PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated." | ( Gee, L; Jacobson, MA; Lugo, D; Robles, R, 1999) |
| "Four young male AIDS patients were therefore treated with 750 mg of UDCA for 4 months." | ( Horn, K; Kurktschiev, D; Schentke, K; Temelkova-Kurktschiev, T, 1999) |
| "Until a new and better therapy for AIDS is found, treatment of patients with AIDS-related lymphoma will be regarded as palliative, and less toxic regimens will be considered." | ( Avilés, A; Halabe, J; Nambo, MJ, 1999) |
| "The emphasis in treating AIDS patients should be compassionate, low technology, cost-effective care." | ( Safaya, AN; Tabish, A, 1991) |
| "In the battle against acquired immune deficiency syndrome (AIDS), focusing treatment on early intervention of its underlying condition, human immunodeficiency virus (HIV) infection, may help reduce the disability associated with AIDS." | ( Cimoch, PJ; Reiter, WM, 1990) |
| "By delaying progression to AIDS, the drug reduces the duration and incidence of hospitalisations in a given time period, resulting in overall decreases in the cost of medical treatment per unit of survival time." | ( Benfield, P; Langtry, HD; Palmer, KJ, 1993) |
| "GM-CSF treatment of monocytes from AIDS patients increased fungistatic activity, and the combination of hrGM-CSF and fluconazole resulted in fungicidal activity." | ( Baldelli, F; Bistoni, F; Francisci, D; Preziosi, R; Tascini, C; Vecchiarelli, A, 1999) |
| "Until December 31st 1997, 163 HIV/AIDS patients were treated with HAART at the Department of Infectious Diseases, Aarhus University Hospital." | ( Black, FT; Jensen-Fangel, S; Larsen, L; Nielsen, LP; Obel, N; Thomsen, HF, 1999) |
| "Two patients with AIDS developed microscopically verified focal cryptococcal lymphadenitis while treated with highly active anti-retroviral therapy for 8 and 15 months." | ( Blanche, P; Ginsburg, C; Gombert, B; Passeron, A; Rigolet, A; Salmon, D; Sicard, D; Stubei, I, 1998) |
| "Apo-2L induced apoptosis in >80% of AIDS-KS cells pretreated with Act D." | ( Ashkenazi, A; Bonavida, B; Mori, S; Murakami-Mori, K; Nakamura, S, 1999) |
| "In this study, 30 AIDS patients without Mycobacterium avium infection were randomized to receive treatment with azithromycin (1200 mg), granulocyte-monocyte colony-stimulating factor (GM-CSF; 250 microg/m2/day for 5 days), or both agents." | ( Cinti, S; Coffey, M; Kazanjian, P; Sullivan, A, 1999) |
| "Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy." | ( Bowen, EF; Cherrington, JM; Emery, VC; Griffiths, PD; Johnson, MA; Lamy, PD, 1999) |
| "A 31-year-old man with the acquired immunodeficiency syndrome who developed toxic epidermal necrolysis (TEN) was successfully treated with intravenous immunoglobulin." | ( Adelstein, S; Crotty, K; Phan, TG; Wong, RC, 1999) |
| "We treated 10 AIDS subjects with GM-CSF for 5 days." | ( Cinti, S; Coffey, MJ; Kazanjian, PH; Peters-Golden, M; Phare, SM, 1999) |
| "A patient with AIDS and chronic diarrhea caused by Enterocytozoon bieneusi was successfully treated with nitazoxanide, producing a complete clinical and parasitological response, while off of antiviral therapy." | ( Bicart-Sée, A; Datry, A; Linas, MD; Massip, P, 2000) |
| "The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment." | ( Cahn, P; Canteros, C; Córdoba, S; Davel, G; Guelfand, L; Hochenfellner, F; Kaufman, S; Rodero, L, 2000) |
| "The findings suggest that although HIV/AIDS-related stigma has had adverse effects on treatment seeking behaviour of PWAs and coping mechanisms of their families, a more tolerant attitude is starting to emerge in this area." | ( Barton, T; Muyinda, H; Pickering, H; Seeley, J, 1997) |
| "Patients with a missing CD4HIV or CD4AIDS were younger and less likely to have received antiretroviral therapy or prophylaxis for Pneumocystis carinii pneumonia (PCP)." | ( Boag, F; Easterbrook, PJ; Gazzard, B; Goetghebeur, E; McLean, K; Yu, LM, 2000) |
| "The observed decline in CD4AIDS value was related to the introduction of antiretroviral therapy in 1988, and PCP prophylaxis in 1989." | ( Boag, F; Easterbrook, PJ; Gazzard, B; Goetghebeur, E; McLean, K; Yu, LM, 2000) |
| "However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet." | ( Delecluse, HJ; Huhn, D; Ruhnke, M; Schneider, U; Stein, H, 2000) |
| "Twenty-nine patients with AIDS were treated with triple antiretroviral therapy, including protease inhibitors, were treated with a chemotherapy regimen involving cyclophosphamide 750 mg/m2, i." | ( Avilés, A; Halabe, J, 1999) |
| "We estimated the AIDS survival by neighborhood socioeconomic status before (1993-1995) and after (1996-1997) the introduction of highly active antiretroviral therapy in Rome, Italy, in a retrospective cohort of persons with AIDS followed through July 31, 1998." | ( Forastiere, F; Fusco, D; Perucci, CA; Porta, D; Rapiti, E, 2000) |
| "The most common superinfection in 28 acquired immunodeficiency syndromes (AIDS) cases was Mycobacterium tuberculosis (100%) responded to MDT but after recurrence there was progressive failure of response to therapy." | ( Redkar, SV; Redkar, VE, 1999) |
| "A patient with AIDS, treated with highly active antiretroviral therapy and trimethoprim-sulfamethoxazole, presented with confusion, a hemifield defect, and a mass lesion in the right occipital lobe." | ( Conde, C; Diz, J; Gonzalez-Mediero, G; Rodriguez De Lope, A; Santiago, P; Seijo Martinez, M; Visvesvara, GS, 2000) |
| "Therefore, 105 individuals with AIDS who were receiving nucleoside analogue therapy were enrolled in a placebo-controlled, double-blind study and were randomized to receive either 125 microgram/m(2) of yeast-derived, GM-CSF (sargramostim) or placebo subcutaneously twice weekly for 6 months." | ( Agosti, JM; Alcantara, AP; Badaro, R; Bahia, F; Brites, C; Essex, M; Gilbert, MJ; Matos, J; Pedral-Sampaio, D; Pedroso, C; Renjifo, B; Sasaki, MD; Whitmore, JB, 2000) |
| "The philosophy of both AIDS and IDU treatment has changed drastically in recent years, due to several factors." | ( Dobs, AS; Wahlstrom, JT, 2000) |
| "Participants in a province-wide HIV/AIDS treatment programme reported morphological and metabolic abnormalities." | ( Chan, KJ; Harris, M; Heath, KV; Hogg, RS; Montanera, JS; Montessori, V; O'Shaughnessy, MV, 2001) |
| "We reported a patient with acquired immunodeficiency syndrome (AIDS)-associated progressive multifocal leukoencephalopathy (AIDS-PML), whose condition improved after highly active anti-retroviral therapy (HAART)." | ( Iwata, M; Ota, K; Shimizu, Y; Takeuchi, M; Yogo, Y, 2000) |
| "52 acquired immunodeficiency syndrome (AIDS)-patients with advanced KS received long-term chemotherapy (71+/-51 weeks) with a mean of 22." | ( Esser, S; Goos, M; Hengge, UR; Rudel, HP, 2001) |
| "In the context of an AIDS clinical trial involving patients treated with a combination of potent antiviral agents, we show how the models may be used to draw biologically relevant interpretations from repeated HIV-1 RNA measurements and demonstrate the potential use of the models in clinical decision-making." | ( Ding, AA; Wu, H, 1999) |
| "For the time to AIDS comparison, 821 men receiving zidovudine therapy before the diagnosis of AIDS were pair matched with men who did not receive zidovudine therapy until after diagnosis on their CD4 cell count (+/- 75 cells/mm3), haemoglobin level (+/- 0." | ( Detels, R; Graham, N; Mellors, J; Muñoz, A; Peng, Y; Phair, J, 1997) |
| "The paradigm of AIDS patient care has evolved to that of a chronic disease that is manageable with combination antiretroviral therapy." | ( Frick, PA; Gal, P; Lane, TW; Sewell, PC, 1998) |
| "The Intercompany Collaboration for AIDS Drug Development (ICC), a consortium of fifteen drug companies, is enrolling volunteers for its first clinical trial of combination drug therapy." | ( , 1995) |
| "Alvin Novick, head of GLMA's AIDS Task Force, the Clinton Administration is being asked to not let its political fears blind it to the positive and legitimate scientific research designed to alleviate the suffering of thousands of AIDS patients." | ( , 1995) |
| "In a two-part interview with AIDS Treatment News (ATN), Margaret Poscher, M." | ( Poscher, M, 1995) |
| "Presentations on HIV- and AIDS-related research, delivered at the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in 1995, are addressed." | ( Gilden, D, 1995) |
| "Topics included how HIV develops into AIDS, the use of antiretroviral therapy in HIV infection, viral invasions of lymphoid tissue, and CMV prophylaxis and resistance." | ( Mascolini, M, 1995) |
| "While AIDS treatment activists supported the approval of all three drugs, they criticized details of the committee's recommendations." | ( Smart, T, 1995) |
| "An interview with five experts on AIDS therapy, Dr." | ( Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C, 1996) |
| "DHEA's background and use as an AIDS treatment are reviewed." | ( James, JS, 1996) |
| "The PWA Health Group, an AIDS buyers' club, is asking the Food and Drug Administration (FDA) to require Merck and Abbott to obtain long-term follow-up data of their drugs, indinavir and ritonavir." | ( James, JS, 1996) |
| "The disparity in the availability of AIDS drugs between the United States and Europe is frustrating to members of the European AIDS Treatment Group, among others." | ( Alcorn, K, 1996) |
| "Sold for years in AIDS buyers' clubs as an alternative treatment for HIV infection, NAC is a low-cost treatment approved for certain non-HIV medical uses." | ( James, JS, 1996) |
| "The International AIDS Society developed clinical recommendations for antiretroviral therapy, including information on when to start treatment, what to change to, and the special considerations of postexposure prophylaxis and primary infection." | ( , 1996) |
| "Early and aggressive AIDS treatment can prevent irreversible damage to the immune system." | ( , 1997) |
| "A 3-drug AIDS treatment trial, ACTG 320, was halted early after it became clinically evident that the therapy was superior to 2-drug combinations in reducing death rates and new AIDS-related illnesses." | ( Baker, R, 1997) |
| "Michael Golk, a person with AIDS who is successfully maintaining a non-detectable viral load using Norvir combined with D4T and 3TC, describes his treatment regimen and use of nutritional supplements." | ( Golk, M, 1998) |
| "Global access to HIV/AIDS treatment was the universal theme at the 12th World AIDS Conference." | ( , 1998) |
| "A 60-year-old African-American man with AIDS developed neutropenia that was probably secondary to antiretroviral therapy." | ( Hejny, C; Kerrison, JB; Newman, NJ; Stone, CM, 2001) |
| "Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment." | ( Budd, DW; Himmelberger, D; Northfelt, DW; Osoba, D, 2001) |
| "The fall in deaths from AIDS enhances the problem to prevent and treat HCV infection." | ( Lechi, A; Lugoboni, F; Mezzelani, P; Quaglio, G; Talamini, G; Venturini, L, 2001) |
| "We report here two patients with AIDS and disseminated Mycobacterium avium infection who developed symptomatic hypercalcaemia several weeks after commencing antimycobacterial chemotherapy, and in whom inappropriately elevated 1,25(OH)(2)D(3)levels were documented." | ( Bansal, AS; Hogan, PG; Looke, DF; Playford, EG; Whitby, M, 2001) |
| "We conclude that patients with AIDS on megace therapy should receive special attention in regards to the potential development of AI, especially in stress situations such as infections or pain." | ( Koch, CA; Pacak, K, 2001) |
| "Acquired immune deficiency syndrome (AIDS) is resistant to all current therapy." | ( Ishikawa, T; Kitamura, T; Kitamura, Y; Kobayashi, N; Okui, N; Sakuma, R, 2001) |
| "Relative hazards (RH) of AIDS, in the absence of highly effective anti-HIV therapy, were estimated for age, HIV-1 viral load, CD4 lymphocyte count and levels of HIV-1 2-LTR circles and TREC [per 106 peripheral blood mononuclear cells (PBMC)]." | ( Goedert, JJ; Hatzakis, A; Kostrikis, LG; O'Brien, TR, 2001) |
| "Patients with acquired immunodeficiency syndrome (AIDS)-associated lymphoma/leukemia have a poor prognosis and are frequently treated with low-intensity therapy." | ( Cortes, J; Faderl, S; Jeha, S; Kantarjian, H; Koller, C; O'Brien, S; Rios, A; Thomas, D, 2002) |
| "Thirteen patients with AIDS-associated Burkitt lymphoma (six patients) or leukemia (acute lymphoblastic leukemia; seven patients) were treated with hyper-CVAD alternating with high-dose methotrexate and ara-C for a total of eight cycles." | ( Cortes, J; Faderl, S; Jeha, S; Kantarjian, H; Koller, C; O'Brien, S; Rios, A; Thomas, D, 2002) |
| "A 35-year-old white man with AIDS received risperidone 2 mg twice daily for treatment of a Tourette's-like tic disorder." | ( Béïque, LC; Bowmer, MI; Kelly, DV, 2002) |
| "A 42-y-o man with AIDS confused his instructions for self-administration of interferon and EPO and began injecting himself daily with 10,000 units of EPO for several weeks." | ( Cobrin, G; Hoffman, RS; Howland, MA; Nelson, LS, 2002) |
| "To estimate the change in AIDS incubation time during three periods characterized by different availability of antiretroviral treatments, data from the French Hospital Database on HIV of 4702 HIV-1-positive subjects with a documented date of infection were analyzed." | ( Bentata, M; Costagliola, D; Deloumeaux, J; Grabar, S; Lancar, R; Tassie, JM, 2002) |
| "Increased support from the global HIV/AIDS community is driving advances in HIV treatment and vaccine development in the developing world." | ( Grant, AD; Macharia, D; Mastro, TD; Nkengasong, J; Weidle, PJ, 2002) |
| "Eligible patients had advanced AIDS-KS consisting of at least 25 mucocutaneous lesions, visceral disease, or lymphedema, and had failed to respond to at least one previous systemic chemotherapy regimen." | ( Espina, BM; Friedman-Kien, A; Garces, C; Gill, PS; Groopman, J; Harrington, W; Mantelle, L; Mettinger, K; Saville, MW; Scadden, DT; Tulpule, A, 2002) |
| "Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy." | ( Bazin, B; Britto, P; Chaix, ML; Cunningham, CK; Delfraissy, JF; Dorenbaum, A; Gelber, RD; Mofenson, L; Rekacewicz, C; Rouzioux, C; Sullivan, JL, 2002) |
| "We describe 2 patients with acquired immunodeficiency syndrome who had potentially fatal bradyarrhythmia that occurred shortly after commencement of antiretroviral therapy." | ( Genka, I; Ishizaki, A; Kikuchi, Y; Oka, S; Sunagawa, K; Yasuoka, A, 2002) |
| "A child with perinatally acquired AIDS and profound immunodeficiency was treated with zidovudine, lamivudine and indinavir and had excellent immunologic and virologic response." | ( Viani, RM, 2002) |
| "When the HIV/AIDS epidemic's toll including 40 million people living with the disease and 3 million having died in 2001, the world's health and service organizations are increasingly calling for better access to care and treatment for people living in the developing nations that share the brunt of the epidemic's devastation." | ( , 2002) |
| "In patients with advanced AIDS-related Kaposi's sarcoma, PEG-liposomal doxorubicin monotherapy produced overall response rates ranging from 46 to 77% in randomised trials." | ( Easthope, SE; Keating, GM; Lamb, HM; Sharpe, M, 2002) |
| "The majority of AIDS patients in Africa rely on traditional healers to treat their disease rather than on Western medicine." | ( Gottingar, V, 1989) |
| "Jackie had to put AIDS treatment on hold to combat multiple drug-resistant tuberculosis yet she never missed a dose of medication." | ( El-sadr, W, 1998) |
| "In this address to the 12th World AIDS Conference, a young HIV- infected mother from South Africa recounted how her baby died after receiving AZT therapy because she was not told the baby could be infected through breast feeding." | ( Maklehemena, M, 1998) |
| "The Uganda AIDS Commission is also considering the use of herbs in the treatment of AIDS; nine Western-trained researchers are collaborating with herbalists in studies that have shown promising results." | ( , 1996) |
| "Most AIDS-educated THs now acknowledge that AIDS exists and are taking protective measures, such as using disposable razor blades to avoid infecting patients with HIV during traditional treatments." | ( Munk, K, 1997) |
| "We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
| "In persons with acquired immunodeficiency syndrome (AIDS), Cryptosporidium parvum causes a prolonged, severe diarrheal illness to which there is no effective treatment, and the risk of developing cryptosporidiosis from drinking tap water in non-outbreak settings remains uncertain." | ( Aragón, TJ; Enanoria, W; Katz, MH; Khalakdina, A; Novotny, S; Vugia, DJ, 2003) |
| "Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms." | ( Bardeguez, AD; Coombs, R; Cunningham, B; Fowler, MG; Frenkel, LM; Gandia, J; Huang, S; Jones, T; Maupin, R; Mofenson, LM; O'Sullivan, MJ; Shapiro, DE; Sperling, RS; Zorrilla, CD, 2003) |
| "The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has improved since the era of highly active antiretroviral therapy, but median survival remains low." | ( Franchini, G; Grant, N; Gutierrez, M; Jaffe, ES; Kavlick, MF; Little, RF; Mitsuya, H; Pittaluga, S; Raffeld, M; Shearer, G; Steinberg, SM; Wilson, WH; Yarchoan, R, 2003) |
| "Seven patients with AIDS-associated PEL were treated with a combined chemotherapy including high-dose methotrexate followed by leucovorin rescue." | ( Agbalika, F; Boulanger, E; Daniel, MT; Oksenhendler, E, 2003) |
| "Incidence rates of AIDS or death were calculated for overall and most recent CD4 count in 6-monthly periods and in three treatment eras (pre-HAART, 1994-1995; early-HAART, 1996-1997; and late-HAART, 1998-2002)." | ( d'Arminio Monforte, A; Dietrich, M; Katlama, C; Kirk, O; Knysz, B; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P, 2003) |
| "Brazilian AIDS and HIV-1-seropositive patients have had free access to highly active antiretroviral therapy (HAART) since November 1996." | ( Brigido, LF; Bueno, A; Casseb, J; de Almeida, A; Duarte, AJ; Ferez, AC; Fonseca, LA; Gonsalez, CR; Malacarne, E; Mendonça, M; Rodrigues, R; Ronchini, KO; Santos, N; Veiga, AP; Zihlmann, KF, 2003) |
| "Changes over time in progression to AIDS and death, hospital admission rates, and use of antiretroviral therapy." | ( Butler, K; Dunn, DT; Duong, T; Farrelly, L; Gibb, DM; Masters, J; Novelli, V; Peckham, CS; Riordan, A; Sharland, M; Tookey, PA; Tudor-Williams, G, 2003) |
| "Three acquired immunodeficiency syndrome-defined patients with neurocognitive impairment were serially evaluated during daily GH treatment showing a sustained improvement in neuropsychological performance (p < 0." | ( Gill, MJ; Holden, JK; Power, C; Silva, C; Tsutsui, S; Zhang, K, 2003) |
| "Any treatment for HIV/AIDS must, therefore, include normalization of body levels of glutathione, glutathione peroxidase, selenium, cysteine, glutamine, and tryptophan." | ( Foster, HD, 2004) |
| "Risk of AIDS was assessed in 3226 subjects with viral load and CD4 cell count known before initiation of antiretroviral therapy or during the zidovudine monotherapy era." | ( Pezzotti, P; Phillips, A, 2004) |
| "We report a patient with acquired immune deficiency syndrome (AIDS) who developed Philadelphia-positive chronic myeloid leukemia (CML) and was successfully treated with imatinib mesylate." | ( Bonnie, G; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Medina, J; Rios, A; Tsimberidou, AM, 2004) |
| "Forty Thai patients with AIDS and cryptococcal meningitis, of whom 20 had been receiving oral rifampicin for at least 2 weeks to treat tuberculosis." | ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "A 53-year-old male patient with acquired immunodeficiency syndrome (AIDS) was treated with topical immunomodulator imiquimod for bowenoid papular." | ( Cavalcanti, SM; Nunes, Mde G; Oliveira, Ldo H; Ramos-e-Silva, M; Trope, BM, 2004) |
| "A 38-year-old male with advanced AIDS, who had failed to respond to triple-drug antiretroviral therapy, underwent baboon BMT in 1995." | ( Damon, L; Gupta, P; Heneine, W; Ildstad, ST; Kaplan, L; Kaufman, C; Michaels, MG; Sandstrom, P; Swift, P; Switzer, WM; Volberding, PA, 2004) |
| "Baboon BMT to treat AIDS was attempted using nonmyeloablative conditioning and resulted in transient microchimerism and clinical and virologic improvements." | ( Damon, L; Gupta, P; Heneine, W; Ildstad, ST; Kaplan, L; Kaufman, C; Michaels, MG; Sandstrom, P; Swift, P; Switzer, WM; Volberding, PA, 2004) |
| "Therapeutic trials for AIDS-Kaposi's sarcoma must account for ongoing immune reconstitution in the setting of concurrent highly active antiretroviral therapy that may confound estimates of therapeutic activity." | ( Aboulafia, D; Dezube, BJ; Gill, P; Lee, J; Noy, A; Scadden, DT; Tulpule, A; Walmsley, S, 2005) |
| "Totally 1,000 AIDS patients were treated, among them 60 patients were clinically observed weekly." | ( Chen, CH; Li, ZL; Liu, XZ; Ma, SW; Wang, Z; Wang, ZM; Wen, RX; Xue, XL; Yue, YC; Zeng, Y; Zhang, ZS; Zhu, XP, 2004) |
| "Although the incidence of most AIDS events declines after initiation of highly active antiretroviral therapy (HAART), this decline is more rapid for some conditions than others." | ( d'Arminio Monforte, A; Dabis, F; Egger, M; Gill, J; Grabar, S; Justice, A; Ledergerber, B; May, M; Phillips, A; Reiss, P; Sabin, CA; Sterne, J, 2005) |
| "The management of early stage cutaneous AIDS-KS has been revolutionized by the introduction of highly active antiretroviral therapy and for most patients highly active antiretroviral therapy alone will control early stage AIDS-KS." | ( Bower, M; Dhillon, T; Stebbing, J, 2005) |
| "All patients had had AIDS for a long time and were using highly active antiretroviral therapy." | ( Almeida, LV; Calore, EE; Ferreira, AF; Horta, SC; Manzione, CR; Nadal, SR, 2005) |
| "Thirty-one men with HIV/AIDS (adhering to highly active antiretroviral therapy for the previous 3 months) were recruited during regular visits to a Veterans Affairs Medical Center Infectious Disease Clinic in a southeastern US city." | ( Bender, BS; Cole, SB; Findley, K; Herrlinger-Garcia, KA; Langkamp-Henken, B; Uphold, CR, 2005) |
| "The decline in AIDS deaths in the USA between 1995 and 2002 has been attributed by Centers for Disease Control (CDC) to HIV treatments advances." | ( Holtgrave, DR, 2005) |
| "Sixty-eight consecutive HIV/AIDS patients attending Medicine out patient department and/or admitted to the wards of All India Institute of Medical Sciences were administered a structured questionnaire by the HIV nurse coordinator." | ( Agarwal, SK; Ahuja, V; Lekshmi, R; Mittal, CM; Pal, H; Wig, N, 2006) |
| "Reductions in HIV/AIDS mortality associated with highly active antiretroviral therapy (HAART) have mainly been reported from Western countries." | ( Chan, KC; Lee, SS; Wong, KH, 2006) |
| "Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide." | ( Altice, FL; Bruce, RD; Friedland, GH; Gourevitch, MN, 2006) |
| "Twenty-one HIV/AIDS patients were orally administered with AG (mainly composed of Fructus Ligustri lucidi, Radix Scutellariae, Radix Astragalus and Eupolyphaga et polyphage) by 20g, twice a day for 4 months." | ( Chen, YX; Sun, LM; Wei, JA, 2006) |
| "Two patients died of other AIDS-related complications before repeated neuroimaging could be performed to assess treatment response, one patient refused to undergo further treatment or follow up, and two patients responded well to treatment." | ( Lilien, DL; Menendez, JA; Nanda, A; Polin, RS, 2000) |
| "Forty AIDS patients were randomly divided into a treatment group and a control group, both treated with HAART." | ( Cheng, C; Chi, Y; Wei, HX; Wu, YW; Yao, WH; Zhao, H; Zhao, W; Zhu, P, 2006) |
| "6-month risks (%) of death, AIDS, and combined risk of AIDS and death (AIDS/death) were calculated according to CD4-cell count category of less than 200 cells per microL, 200-350 cells per microL, or greater than 350 cells per microL, stratified by WHO clinical stages 1 and 2 combined, 3, or 4 in untreated patients (n=1399) seeking care in tertiary public-sector HIV clinics before widespread availability of ART in Cape Town, South Africa." | ( Badri, M; Lawn, SD; Wood, R, 2006) |
| "Of 60 AIDS patients, 32 patients had received highly active antiretroviral therapy and received subsequent assessment of lymphocyte cell counts 1 month later." | ( Huang, TL; Leu, HS; Liu, JW, 2006) |
| "Households affected by an HIV/AIDS-related death can be forced to sell their means of production to cover the high economic burden of treatment and other costs associated with HIV/AIDS." | ( Balasubramanian, R; Muniyandi, M; Ramachandran, R, 2006) |
| "Despite a decreased incidence of AIDS-related Kaposi's sarcoma (KS) due to the advent of highly active antiretroviral therapy, approximately 15% of AIDS patients still develop AIDS-related KS." | ( Cooley, T; Henry, D; O'Connell, M; Rackoff, W; Sun, S; Tonda, M, 2007) |
| "In 2003, adults with HIV/AIDS were recruited through 114 US STD/HIV clinics to complete self-administered questionnaires." | ( Ambegaonkar, BM; Bolge, SC; McDonnell, DD; Mody, S; Zilberberg, MD, 2007) |
| "We also examined TM polymorphism in two AIDS patients under HAART and T-20 therapy." | ( Jessen, H; Kücherer, C; Morozov, AV; Morozov, VA; Schürmann, D, 2007) |
| "Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone." | ( Destiche, DA; Frincke, JM; Garsd, A; Noveljic, Z; Stickney, DR, 2007) |
| "In the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study, 918 HIV-1-infected men and women who were not using antiretroviral therapy were followed for a median of 5." | ( Anastos, K; Cole, SR; Hernán, MA; Jamieson, BD; Robins, JM, 2007) |
| "Thirty-six patients with AIDS-associated Kaposi sarcoma (KS) requiring chemotherapy were treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly), followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years." | ( Aleman, K; Catanzaro, AT; Kumar, P; Little, RF; Pittaluga, S; Pluda, JM; Read-Connole, E; Steinberg, SM; Wang, V; Wyvill, KM; Yarchoan, R, 2007) |
| "A retrospective study of 30 AIDS patients with CMV retinitis treated between 1997 and 2007 in Serbia was conducted to examine the prognosis and factors associated with survival." | ( Brmbolić, B; Djurković-Djaković, O; Dujić, M; Jevtović, Dj; Ranin, J; Salemović, D, 2008) |
| "A 35-year-old AIDS patient, on antiretroviral therapy (ART) with stavudine, nevirapine, and lamivudine, developed bilateral ocular congestion and irritation." | ( Jain, V; Natarajan, S; Shome, D, 2008) |
| "Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients." | ( Abrams, DI; Baker, JV; Cavert, WP; Henry, WK; MacArthur, RD; Neaton, JD; Peng, G; Rapkin, J; Silverberg, MJ, 2008) |
| "We present a case of a person with AIDS who was receiving chemotherapy for Burkitt lymphoma in whom fatal adenovirus pneumonia and adenoviremia developed, and we review the published literature on adenovirus infection in the setting of HIV disease." | ( Adeyemi, OA; Ison, MG; Yeldandi, AV, 2008) |
| "However, the behavior of OL in HIV/AIDS patients undergoing highly active antiretroviral therapy including efavirenz (HAART/EFV) has not been documented." | ( Acosta-Gio, AE; Aquino-García, SI; Ceballos-Salobreña, A; Gaitán-Cepeda, LA; Rivas, MA, 2008) |
| "Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients." | ( Bourinbaiar, AS; Jirathitikal, V; Metadilogkul, O, 2009) |
| "We selected 4 AIDS patients receiving highly active antiretroviral therapy (HAART) with good adherence under a HIV-1 drug resistance cohort from a rural region in central China." | ( Bao, ZY; Jiao, LY; Li, H; Li, HP; Li, J; Li, JY; Li, L; Liu, SY; Liu, YJ; Wang, Z; Zhuang, DM, 2008) |
| "Part of HIV/AIDS patients showed resistant to genotype drugs in Henan province, suggesting that we must reinforce the surveillance on HAART and program on drug administration to the patients, in order to increase the number of CD4+ T-lymphocyte so as to avoid the development of drug resistance." | ( Cui, WG; Li, H; Liu, CH; Liu, HW; Wang, Z; Yuan, Y; Zhu, Q; Zhu, XP, 2008) |
| "The risk of AIDS or death, by whether or not an infant started treatment before 3 months of age, was estimated by Kaplan-Meier survival analysis and Cox proportional hazards models." | ( Dollfus, C; Galli, L; Giaquinto, C; Gibb, D; Goetghebuer, T; Green, H; Haelterman, E; Judd, A; Le Chenadec, J; Levy, J; Ramos, JT; Warszawski, J, 2009) |
| "We report a case involving an AIDS patient with an Aspergillus fumigatus brain abscess who survived for longer than 10 months after surgical drainage and therapy with voriconazole." | ( Anderson, AM; Diazgranados, CA; Gongora, MC; Hidron, AI, 2009) |
| "Patients with Acquired Immunodeficiency Syndrome (AIDS) were recruited under the Federal Government Highly Active Antiretroviral Therapy (HAART) programme at the University of Ilorin Teaching Hospital." | ( Iseniyi, JO; Odeigah, L; Olatunji, PO; Olawumi, HO; Salami, AK, 2008) |
| "Brazil's large-scale, successful HIV/AIDS treatment programme is considered by many to be a model for other developing countries aiming to improve access to AIDS treatment." | ( Fonseca, ED; Gruskin, S; Nunn, A, 2009) |
| "Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS." | ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, PC; Kendrick, AS; Kopetskie, H; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K, 2009) |
| "neoformans in samples of CSF of an AIDS patient with cryptococcosis treated at the University Hospital of Infectious Disease is presented." | ( Bava, J; Isla, G; Solari, R; Troncoso, A, 2008) |
| "Pain induced by AIDS therapy represents a progressive problem and induces the necessity to alter the highly active antiretroviral therapy (HAART)." | ( Evers, S; Hahn, K; Husstedt, IW; Kästner, F; Reichelt, D, 2009) |
| "Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings." | ( De Beaudrap, P; Delaporte, E; Diouf, A; Ecochard, R; Etard, JF; Ndèye, GF; Ndèye, KC; Ndiaye, I; Sow, PS, 2010) |
| "In a randomized trial, AIDS Clinical Trials Group (ACTG) protocol 5146 (A5146) investigated the use of therapeutic drug monitoring (TDM) to adjust doses of HIV-1 protease inhibitors (PIs) in patients with prior virologic failure on PI-based therapy who were starting a new PI-based regimen." | ( Albrecht, M; Demeter, LM; DiCenzo, R; DiFrancesco, R; Dykes, C; Jiang, H; Morse, GD; Mukherjee, AL; Rinehart, A; Rosenkranz, S, 2010) |
| "The treatment of AIDS remains a serious challenge owing to high genetic variation of Human Immunodeficiency Virus type 1 (HIV-1)." | ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S, 2010) |
| "These eight subsystems cover: (i) HIV/AIDS case reporting; (ii) HIV testing and counselling; (iii) antiretroviral treatment (ART) for adults; (iv) ART for children; (v) behavioural interventions for high-risk groups; (vi) methadone maintenance treatment; (vii) sentinel and behavioural surveillance; and (viii) local county background information." | ( Ma, W; Ma, Y; Mao, Y; Poundstone, K; Qin, Q; Wang, C; Wu, Z, 2010) |
| "Prophylaxis in AIDS patients seems to be a major problem area and a lot of efforts need to be directed toward it since patients suffering from AIDS are bound to have a downhill course despite provision of all available treatment options." | ( Guleria, R; Jain, SB; Mishra, N; Nagpal, SJ; Pandey, RM; Sharma, SK; Vajpayee, M; Wig, N, 2011) |
| "Diarrhea in patients with acquired immunodeficiency syndrome (AIDS) may cause malabsorption of medications and failure of antiretroviral therapy (ART)." | ( Beauharnais, CA; Dillingham, R; Dupnik, K; Eyma, E; Fitzgerald, D; Guerrant, R; Jennings, S; Kashuba, A; Leger, P; Miller, E; Pape, J; Samie, A, 2011) |
| "People living with HIV/AIDS (PLHA) while availing anti-retroviral therapy (ART) services face administrative and procedural problems in hospitals which affect their level of satisfaction with service providers." | ( Devnani, M; Gupta, AK; Sharma, RK; Wanchu, A, 2012) |
| "A 49-year-old man with advanced HIV/AIDS on anti-retroviral therapy (HAART) and trimethoprim-sulfamethoxazole (TMP-SMX) presented with a several-month history of pruritic, erythematous, lichenified papules that coalesced into hyperkeratotic plaques on the trunk and extremities in a sun-exposed distribution." | ( Hartman, R; Meehan, S; Pomeranz, MK; Sanchez, M; Sanders, SE; Tran, K; Tzu, J, 2011) |
| "By cross-sectional survey, 378 AIDS patients who had received the national free antiretroviral therapy from July 2003 to March 2009 in Zhecheng county of Henan were selected." | ( Liu, CH; Liu, HW; Ruan, YH; Shao, YM; Wang, X; Wang, XY; Wang, Z; Xing, H; Yang, LT; Yuan, Y; Zheng, BF, 2011) |
| "The cytomegalovirus retinitis in the AIDS patients was response well to ganciclovir therapy." | ( He, T; Liu, L; Lu, H; Shen, Y; Shi, Y; Yang, Y; Zhang, R; Zhang, Y; Zhang, Z; Zheng, Y, 2011) |
| "Anti-HIV/AIDS gene therapy is one of the most promising strategy, although challenging, to eradicate HIV-1 infection." | ( Alberici, L; Bovolenta, C; Porcellini, S, 2013) |
| "The work related to AIDS second-line antiretroviral therapy in Henan should be more opportune, rigorous and standardized." | ( Cui, WG; Dou, ZH; Liu, CH; Liu, J; Wang, Z; Wu, YS; Zhu, Q; Zhu, XP, 2012) |
| "Raltegravir (RAL), commonly used in AIDS therapy, belongs to the family of IN ST inhibitors (INSTIs) acting on IN-viral DNA complexes (intasomes)." | ( Abdel-Azeim, S; Ammar, FF; Fermandjian, S; Hobaika, Z; Maroun, RG; Zargarian, L, 2012) |
| "Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood." | ( Biague, AJ; da Silva, ZJ; Esbjörnsson, J; Fenyö, EM; Isberg, PE; Jansson, M; Kvist, A; Månsson, F; Medstrand, P; Norrgren, H; Nowroozalizadeh, S, 2012) |
| "The incidence of certain non-AIDS-defining cancers (NADCs) in HIV patients has been reported to have increased in the combination antiretroviral therapy (ART) era." | ( Abrams, DI; Chao, C; Horberg, MA; Klein, D; Leyden, WA; Quesenberry, CP; Silverberg, MJ; Towner, WJ; Xu, L, 2012) |
| "Strongyloidiasis may be prevalent in AIDS patients in the USA who emigrated from Ss-endemic countries, but serology can be inconclusive, suggesting that empiric ivermectin therapy is a reasonable approach in AIDS patients originating from Strongyloides endemic areas." | ( Krishnan, S; McAuliffe, I; Mejia, R; Nabha, L; Nutman, T; Ramanathan, R; Roby, G; Sereti, I; Sheikh, V, 2012) |
| "A total of 118 HIV/AIDS patients were divided into 3 groups: untreated group (40 patients), highly active antiretroviral therapy (HAART) for 1 - 2 years group (37 patients) and HAART over 5 years group (41 patients), with 20 healthy individuals as the control group." | ( Han, Y; Li, TS; Li, YL; Qiu, ZF; Song, XJ; Su, YB; Xie, J; Yu, W, 2012) |
| "Rapid diagnosis of HIV/AIDS enables the development of prevention and treatment programmes but accurate, reliable and cost effective testing strategies should be used for testing of HIV/AIDS from a large population." | ( Ahmad, B; Hayat, K; Waheed, U; Waheed, Y; Zaheer, HA, 2013) |
| "Progression towards AIDS can vary from 5 to 10 years from the establishment of the primary infection by HIV-1 to more than 10 years in the complete absence of antiretroviral therapy." | ( Amorim, R; Costa, LJ; Cruz, NV; Oliveira, FE; Speranza, FA, 2013) |
| "HIV-1 viral load is used to monitor AIDS progression and effect of antiretroviral therapy (ART)." | ( Ballesteros-Zebadúa, P; Cocho, G; Estrada, JL; Huerta, L; Villarreal, C, 2013) |
| "Long-term survival for patients with AIDS-related diffuse large B-cell lymphoma (DLBCL) is feasible in settings with available combination antiretroviral therapy (cART)." | ( de Witt, P; Maartens, DJ; Sissolak, G; Uldrick, TS, 2013) |
| "Two-year OS for patients with AIDS-related DLBCL treated with CHOP like regimens and cART is comparable to that seen in the United States and Europe." | ( de Witt, P; Maartens, DJ; Sissolak, G; Uldrick, TS, 2013) |
| "A total of 117 adult HIV/AIDS patients on stavudine-containing antiretroviral therapy (ART) were recruited from the ART clinic at the Queen Elizabeth Central Hospital, Malawi." | ( Dandara, C; Kampira, E; Kumwenda, J; Van Oosterhout, JJ, 2013) |
| "New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43-0·96; p=0·031), tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28-0·89, p=0·018), and primary non-AIDS events were rare (12 in the early group vs nine with delayed treatment)." | ( Anderson, M; Celentano, D; Chariyalertsak, S; Chen, YQ; Cohen, MS; de Melo, MG; Eron, J; Eshleman, SH; Essex, M; Gallant, J; Gamble, T; Godbole, SV; Grinsztejn, B; Hakim, JG; Havlir, D; Hoffman, I; Hosseinipour, MC; Kumarasamy, N; Kumwenda, J; Makhema, J; Mayer, KH; McCauley, M; Mills, LA; Nielsen-Saines, K; Ou, SS; Panchia, R; Pilotto, JH; Piwowar-Manning, E; Ribaudo, HJ; Sanne, I; Swindells, S; Taha, TE; Wang, L, 2014) |
| "CD4 cell count, plasma HIV viral load, AIDS-defining illness, hepatitis C co-infection, mortality) and treatment variables (e." | ( Cescon, A; Cui, Z; Harrigan, PR; Hogg, RS; Lepik, KJ; Lima, VD; Montaner, JS; Moore, D; Nosyk, B; Patterson, S; Samji, H; Shannon, K; Wood, E; Yip, B, 2015) |
| "Having an acquired immune deficiency syndrome (AIDS)-defining event or hepatitis C was associated with higher Cho; lower Cho levels, however, were associated with low thiamine levels and with highly active antiretroviral HIV treatment (HAART)." | ( Mayer, D; Pfefferbaum, A; Rohlfing, T; Sullivan, EV; Zahr, NM, 2014) |
| "A study on the records of HIV/AIDS patients attending Habibi Herbal Clinic, Kumasi, Ghana, was conducted to obtain information on the initial viral load presented during their maiden visit and results after treatment with the herbal decoctions." | ( Dapaah, G; Dickson, R; Ekuadzi, E; Gbedema, SY; Koffuor, GA; Otoo, LF, 2014) |
| "A total of 435 HIV/AIDS patients were recruited, among which 108 cases in antiviral treatment and heroin group, 93 cases in antiviral treatment and never using drug group, 105 cases in no antiviral treatment and using heroin group, 129 cases in no antiviral treatment and never using drug group." | ( Chen, H; Chen, R; Huang, J; Jiang, J; Liang, B; Liang, H; Pan, P; Yang, X; Ye, L; Zhao, F; Zhou, B, 2014) |
| "Data on AIDS patients initially starting antiretroviral therapy during 2008 and 2013 were collected from Chinese HIV/AIDS integrated control system." | ( Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| "The viral suppression efficacy among AIDS patients with different baseline immunologic levels after treatment was similarly satisfactory." | ( Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| "When patients with penicilliosis/AIDS were diagnosed early and treated with standardized antifungal therapy and combined antiretroviral therapy, their prognosis improved." | ( Cao, Q; Deng, L; Gui, X; Lio, J; Yan, Y; Yang, R; Zheng, J, 2015) |
| "We projected the 1990-2020 AIDS deaths for Nigeria and South Africa using four treatment scenarios: 1) no ART; 2) maintaining current ART coverage; 3) 90% ART coverage based on 2013 World Health Organization (WHO) ART guidelines by 2020; and 4) reaching the United Nations 90-90-90 Target by 2020." | ( Granich, R; Gupta, S; Hersh, B; Montaner, J; Williams, B; Young, B; Zuniga, JM, 2015) |
| "From 1995-2013, HIV/AIDS cases among former blood donors in Hebei Province were registered and closely monitored to collect data of all-cause mortality, intervention measures to prevent family transmission, disease transmission between couples as well as between mothers and infants, and HAART therapy outcomes." | ( Bai, G; Chen, S; Li, B; Liang, L; Lu, X; Zhang, Y; Zhao, C; Zhao, H, 2015) |
| "Toxoplasmic encephalitis in AIDS patients was usually treated with sulfonamides combined with other drugs and the pooled CR was 49." | ( Lindsay, DS; Peng, HJ; Wei, HX; Wei, SS, 2015) |
| "To investigate the survival rate of AIDS patients after receiving antiretroviral therapy(ART) in Henan province and to determine factors associated with survival status." | ( Fan, P; Li, N; Liang, Y; Nie, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| "Around 15-30% of AIDS patients fail to recover their CD4(+) T cell levels following combined antiretroviral therapy despite successful inhibition of HIV-1 replication." | ( Al-Balushi, MS; Al-Jabri, AA; Al-Mahrooqi, SH; Balkhair, A; El-Beeli, M; Hasson, SS; Said, EA; Youssef, RM; Zadjali, F, 2016) |
| "A patient diagnosed with AIDS had multiple relapses of cryptococcal infection, which became refractory to antifungal agents during the course of therapy." | ( de Carvalho Santana, R; de Gaitani, CM; Dos Santos Quaglio, AS; Martinez, R; Schiave, LA, 2017) |
| "Treatment of HIV has reduced HIV/AIDS-related mortality." | ( Chimukangara, B; Katzenstein, D; Manasa, J; Masimirembwa, C; Mitchell, R; Nyabadza, G, 2017) |
| "Although AIDS-related malignancies are a common feature of late-stage disease, patients under successful antiretroviral therapy also have an increased risk for development of non-AIDS malignancies." | ( Brites, C; Leal, M; Luz, E; Marques, M; Netto, EM; Oliveira, JV; Patrício, R, 2018) |
| "We report an AIDS patient with a high HIV RNA copy number in the plasma who was successfully treated for prolonged Mycobacterium avium bacteremia and other complications." | ( Baba, M; Furukawa, Y; Hamada, H; Hashiguchi, T; Inoue, H; Kamikawaji, K; Okamoto, M; Tashiro, Y; Unoki, T, 2020) |
| "Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation." | ( Cocklin, S; Dick, A, 2020) |
| "The goal of current AIDS-KS treatment modalities is to reconstitute the immune system and suppress HIV-1 replication, but newer treatment modalities are on horizon." | ( Kaondera-Shava, RF; Lungu, E; Szomolay, B, 2021) |
| "A critical burden of AIDS therapy is the evasive nature of HIV-1 in face of host immune responses, the so-called "latency." | ( Salahong, T; Schwartz, C; Sungthong, R, 2021) |
| "A 61-year-old male with HIV/AIDS who was not on antiretroviral therapy and had advanced immunosuppression with a CD4+ T-lymphocyte count of 3 cells/μL sought medical attention for multiple somatic issues including subjective fevers, shortness of breath, and intermittent chest pain." | ( Akram, B; Drevets, DA; Gujju, VR; McGhee, MA; Shibib, DR, 2021) |
| "AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; ESR: erythrocyte sedimentation rate; PPD:purified protein derivative; HE: Hematoxylin and eosin; PAS: Periodic acid-Schiff; CMV: cytomegalovirus; GMS:Gomori's methenamine silver nitrate." | ( Guo, W; Liang, K; Tan, Y; Wu, M; Zhang, Z; Zou, S, 2023) |
| "Moreover, the AIDS patients treated with abacavir or zidovudine had lower VTP values than those without such therapies." | ( Dong, Z; Wang, X; Yan, Q, 2022) |
| "We described two cases of AIDS-related secondary HLH treated with ruxolitinib." | ( Huang, Y; Liu, X; Wan, Z; Xiang, D; Xie, Y; Zhou, X; Zhu, B; Zhu, X, 2022) |
| "marneffei infection in HIV/AIDS patients receiving antiretroviral therapy (ART)." | ( Chen, J; Chen, R; Chen, X; He, J; Jiang, J; Liang, H; Liao, Y; Lu, B; Qin, F; Qin, T; Shi, M; Tao, X; Wang, G; Wei, W; Wu, Y; Ye, L; Zhang, H, 2022) |
| "Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage." | ( André, K; Bessede, E; Blanc, P; Bonnet, F; Cazanave, C; Duffau, P; Lazaro, E; Leleux, O; Neau, D; Pereyre, S; Perrier, A; Saunier, A; Vandenhende, MA; Vareil, MO; Wittkop, L, 2023) |
| "Newly diagnosed, treatment-naive HIV/AIDS patients were randomly sampled from Fujian province in 2015 and 2020." | ( Chen, L; Feng, Y; Lian, Q; Lin, L; Lu, X; Qiu, Y; Wang, D; Wang, W; Wang, Z; Wu, S; Xie, M; Xing, H; Yan, P; Zhang, C, 2023) |